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The Prp2 protein of Saccharomyces cerevisiae is a lOOkDa non-snRNP splicing 
factor with amino acids common to the DEAD/H-box family of ATP-dependent 
RNA helicases. Prp2, Prpl6 and Prp22 proteins have extensive sequence similarity, 
and function at sequential steps in the splicing pathway. Prp2 and Prpl6 form 
transient reactions with the spliceosome, Prp2 at step 1 and Prp16 at step 2. 
In addition to the conserved motifs of the DEAD/H-box family, Prp2 also contains a 
sequence resembling a zinc finger motif. This sequence has been extensively 
mutagenised, and two mutations were found by in vivo complementation assays to 
affect the function of Prp2. 
In order to study the molecular interactions of Prp2 at step 1, several dominant 
negative PRP2 alleles had been generated previously in this laboratory by site-
directed mutagenesis. When overexpressed from an inducible promoter, these cause 
accumulation of pre-mRNA in the presence of wild-type PRP2. These dominant 
negative alleles and wild-type PRP2 were subjected to deletion analyses. In the case 
of one dominant negative mutant which has a GKT to AKT change in the ATP-
binding motif, some dominant activity was retained despite the removal of l9kDa 
from the protein. 
It has been suggested that the Prp 16 protein plays a proofreading role in splicing, as a 
mutant of PRP16, prpl6-1, suppresses an A-C change of the branch nucleotide. A 
mutation analogous to the prpl6-1 allele was created in PRP2 to determine if Prp2 
plays a role in influencing the fidelity of splicing. Although no effect was found for 
this and other mutants of PRP2, it was discovered that overexpression of wild-type 
PRP16 had an effect similar to that of the prpl6-1 mutant on the fidelity of splicing. 
A new hypothesis is proposed for the mechanism of suppression of branchpoint 
mutants by Prpl6 whereby the Prpl6 protein might mediate the binding of an 
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1.1 Intervening sequences in eukaryotes. 
Many eukaryotic genes are interrupted by intervening sequences or introns. Berget et al 
first proposed in 1977 that introns were spliced out of heterogeneous nuclear RNA 
(hnRNA) transcripts in the nucleus to produce mature messenger RNA (niRNA). This 
is the process whereby nuclear pre-mRNA introns are accurately spliced out resulting in 
mature mRNA and an excised intron with a branched, lariat structure. Conserved 
sequences in the intron are known to be involved in directing the splicing reaction 
(Padgett et al, 1986) which occurs in a large multicomponent protein/RNA complex 
known as the spliceosome. 
Nuclear pre-mRNA splicing is one of four known mechanisms of RNA splicing and is 
analogous to the splicing of group II introns. Group II introns are removed via two 
transesterification reactions which also results in the formation of a branched intron-
lariat structure (Cech and Bass, 1986; for recent review, see Michel and Ferat, 1995). 
Although some introns have been shown to be self-splicing in vitro (Peebles et al, 1986; 
Van der Veen et al, 1986; Schmelzer et al, 1986), most group II introns depend on 
proteins for in vivo activity. As in nuclear pre-mRNA splicing, there are many RNA 
helices formed and dissociated during the splicing process which are likely candidates 
for the action of RNA helicase proteins. 
The other two classes of intron, transfer RNA (tRNA) introns and group I introns are 
spliced by different mechanisms resulting in the intron being excised as a linear 
molecule (Culbertson and Winey, 1989; Cech and Bass, 1986). 
In the yeast Saccharomyces cerevisiae, very few structural genes are known to have 
introns, although most ribosomal genes do. All intron-containing structural genes have 
only one intron, with the exceptions of MA Ta] (Miller, 1984) and RPL8A which contain 
two. 
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1.2 Cis-acting elements. 
Comparison of DNA sequences led to the discovery of conserved regions around the 5' 
cut site and the 3' cut site in mammalian genes. In addition, a run of pyrimidines is 
found upstream of the 3' conserved region in mammalian introns (Breathnach et al, 
1978; Mount, 1982). Yeast sequences were shown to agree with the mammalian 
consensus sequences but with a higher degree of conservation. However, many yeast 
genes lack the polypyrimidine tract downstream of the branch nucleotide present in 
higher eukaryotic introns. In addition, yeast introns also had a highly conserved 
sequence around the branchpoint nucleotide (Leer et al, 1984; Teem et a!, 1984). (Table 
1.1) 
Table 1.1 Conserved sequences in mammalian and yeast introns. 
5' splice site branchpoint 3' splice site 
Mammalian ug/GUAGU UNCURAC (Y)nNAG/g 
Yeast /GUAUGU UACUAAC YAG 
Table 1.1 Capital letters indiacte intron sequence and lower case indicates coaing 
sequence. 
The higher conservation of these sequences in yeast partly explains why yeast transcripts 
can be spliced in mammalian systems, while mammalian transcripts cannot be spliced in 
yeast (see section 1.4). The distance between the branchpoint sequence and the 3' 
splice-site in mammalian introns, usually between 18 and 40 nucleotides, is important in 
the selection of the branch nucleotide. In yeast introns, the branchpoint is typically 
between 20 and 40 nucleotides upstream of the 3' splice-site. 
1.3 Mechanisms of splicing. 
The first report of the presence of branched RNA in the nucleus (Wallace and Edmonds 
1983) suggested that mRNA in the cytoplasm was produced as a result of hnRNA being 
processed in the nucleus. Branched RNA was proposed to be the cause of a block to 
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reverse transcriptase in in vitro splicing experiments (Ruskin et al, 1984). The intron 
was shown to be spliced out in the form of a lariat with a 2'-5' phosphodiester linkage in 
a way similar to group II introns (Domdey et al, 1984). A conserved adenosine 
nucleotide in the branchpoint sequence is used in the branch formation in yeast. In vitro 
studies of the splicing pathway showed it to be a two-step process in both mammalian 
and yeast systems (Zeitlin and Estradiatis, 1984; Rodriguez et al, 1984). Step 1 involves 
nucleophilic attack by the 2' hydroxyl group of the branchpoint adenosine on the 5' 
splice site 3',5' phosphodiester bond, and concomitant formation of a branched, lariat 
intermediate with the 5' terminal guanosine of the intron covalently associated by means 
of a 2',5'-phosphodiester bond to the branch adenosine. Step 2 involves attack by the 
3'hydroxyl group of exon 1 on the phosphodiester bond at the 3' splice site, and ligation 
of the two exons (figure 1.1). 
1.4 Mammalian and yeast splicing. 
Methods for studying splicing in vitro were developed for both mammalian and yeast 
systems (Ruskin et al, 1984; Lin, 1985). It was found that Mg 
21 ions and ATP were 
required for splicing to occur ( Kramer et al, 1984; Lin, 1985). The phosphates in the 
new phosphodiester bonds are provided by the splice site phosphates of the pre-mRNA 
and not from exogenous ATP (Padgett et al, 1984; Kornarska et a!, 1985; Lin et a!, 
1985). The ATP involved in splicing is likely to be involved in allowing 
conformational changes within the spliceosome to occur during the splicing process. 
The yeast in vitro system was shown to be accurate by comparing splicing reactions 
with those in vivo. 
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Figure I.I. Mechanism of pre-mRNA splicing. 
	
oj pGUAUGU 	 UACUAACA 	 YAGp tsiiw1 
5' splice site branchpoint region 3' splice site 
VIA 
'2 
— UACUXACA  
1  p _______ 
UACUAACA 	YAG 3'OH 
Figure I.I. Nuclear pre-mRNA splicing consists of two transesterification reactions. The 
first, step 1, involves cleavage at the 5' splice-site of the intron and formation of the 
branched lariat-exon 2 intermediate and free exon 1. Step 2, which is ATP-dependent 
involves cleavage at the 3' splice-site and joining of the two exons to form the mature 
mRNA. The lariat is subsequently debranched and then degraded. 
The development of in vitro splicing systems allowed the direct comparison of 
mammalian and yeast splicing mechanisms. Transcripts which were found to splice 
normally both in vitro and in vivo in yeast, were also found to splice in mammalian in 
vitro systems. One difference found was that the branchpoint nucleotide was variable in 
the HeLa splicing system, both between and within introns, and functionally constrained 
in yeast. Further to this, when the usual branchpoint sequence was removed from the 
transcript, splicing still occurred in HeLa extracts using an alternative branchpoint 
nucleotide which cannot be used by the yeast system (Ruskin et al, 1986). Plant introns 
have also been shown to splice in mammalian in vitro systems (Brown et al, 1986). 
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Earlier in vivo assays have shown that mammalian transcripts cannot' be spliced by 
yeast, using a rabbit 3-globin gene on a yeast plasmid (Beggs et al, 1980). This is in 
part due to the branchpoint sequence being more variable in mammalian transcripts than 
in yeast. Yeast transcripts lacking this branchpoint sequence are not spliced (Langford 
and Gallwitz, 1983). 
Although there are some differences in splicing between yeast and higher eukaryotes, 
yeast is an ideal model system in which to study splicing. As yeast can exist in both 
haploid and diploid states, it is possible to carry out detailed genetic experiments as well 
as biochemical assays. 
1.5 Trans-Acting factors. 
Group II introns, found in fungal and plant mitochondria, plant chloroplasts and algae, 
have conserved secondary structure which brings the splice sites and branchpoint 
together to enable splicing to occur (reviewed by Michel and Ferat, 1995). Group IT 
introns can be spliced autocatalytically in vitro. Nuclear pre-mRNA splicing lacks these 
secondary structure elements, and an increasing body of evidence supports the theory 
that trans-acting factors must be responsible for arranging the pre-mRNA in the correct 
conformation for splicing (for reviews, see Wise, 1993; Weiner, 1993 and Nilsen, 
1992). 
Trans-acting factors involved in splicing in yeast and higher eukaryotes are proteins and 
small nuclear RNAs (snRNAs). Each snRNA is associated with proteins to form small 
nuclear ribonucleoprotein particles or snRNPs. 
There are 5 small nuclear RNAs associated with the spliceosome. These are Ui, U2, 
U4, U5 and U6. Each snRNP takes its name from the associated snRNA e.g. U  snRNP. 
There are a series of core proteins which are associated with each snRNP. These are 
known in mammalian splicing to be B, B', Dl, D2, D3, E, F and G. In addition, there 
are some proteins specific to particular snRNPs, such as U1A, U1C and U2B". 
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A multicomponent RNA-protein complex now known as the spliceosome was first 
isolated from HeLa cell nuclear extracts as a 60S complex from HeLa cells on a glycerol 
gradient (Grabowski et al, 1985). Denaturing gel electrophoresis of extract incubated 
with 32P-labelled transcript under splicing conditions showed that these complexes 
contained precursor RNA (pre-mRNA), splicing intermediates and mature mRNA. 
When treated with protease or detergents, the RNA was no longer associated with the 
protein. The S and 3' consensus sequences were also shown to be involved, as a smaller 
complex was isolated following deletion of sequences 3' of the 5' splice site. 
Another such study showed by means of a timecourse experiment that different-sized 
complexes were assembled sequentially during the splicing reaction (Frendeway and 
Keller, 1985). Using sucrose gradients, a 22S complex was the first to form, followed 
by a 35S complex, and finally by a SOS complex. It was also found that formation of the 
50S complex required ATP. Mature mRNA was found at the top of the gradients 
indicating release from the complex after processing. 
In yeast, a 40S complex was found associated with splicing precursor, intermediates and 
product. By using non-hydrolysable analogues of ATP, its assembly was also found to 
be ATP-dependent. When the conserved 5' splice-site and branchpoint sequences were 
mutated, splicing was found to be blocked (Brody and Abelson, 1985). 
In yeast splicing reactions, three complexes are formed during spliceosome assembly, 
called complex I, II and ifi after their relative electrophoretic mobility in non-
denaturing gels (Pikielny et al, 1986). An alternative naming system calling these 
complexes Al, A2-1, A2-2 and B respectively was proposed by Cheng and Abelson in 
1987. Gel electrophoresis following time-course experiments of splicing in vitro have 
shown that the complexes are formed in the order ifi, I, II , and that complex II is the 
active spliceosome. 
The first PRP (for precursor RNA processing) genes were isolated in a screen to identify 
genes involved in ribosome formation or assembly (Hartwell et al, 1970). It was later 
shown that Hartwell's mutants, prp2-10111 (originally named rna2-10111) accumulated 
intron-containing RNA precursors (Lustig et al, 1986). Many prp mutants are 
temperature-sensitive (ts), showing the defect at the restrictive temperature. Lin et al 
(1987) then went on to show that several of these PRP genes were involved in 
spliceosome assembly, using heat-inactivated mutant extracts. In the case of prp2 
mutant extracts, it was shown that a 40S complex did form, but these complexes 
contained only precursor RNA, and no intermediates or products. However splicing 
was shown to occur in these complexes on the addition of complementing PRP2 
splicing extracts and ATP. 
Since then, around 35 PRP genes have been identified (Vijayraghaven et a!, 1989; Ruby 
and Abelson, 1991; Maddock et al, 1996; Weidenhammer et a!, 1996; Kao and 
Siliciano,1996). The screens carried out so far have not been exhaustive and there are 
thought to be more genes still unidentified. Some PRP genes are known to encode 
component parts of snRNP particles, e.g. Prp8 is a known US snRNP protein (Lossky et 
al, 1987). 
In addition to the PRP genes, a number of other splicing mutants have been identified 
including BrrI to 5, and Ssf] (Noble and Guthrie, 1996; Ansari and Schwer, 1995;). 
In the PRP genes which have been sequenced so far, motifs have been identified which 
indicate the possible function of some of these proteins. Prp4 and Prpl7 proteins has 
been shown to have regions of homology to the n-subunits of G proteins (Dalrymple et 
a!, 1989). The homologous regions may be involved in association or dissociation of 
Prp4 protein with complexes during the splicing pathway. 
Prp 6 and 9 proteins both have sequence motifs similar to metal-binding fingers and 
may be involved in RNA-binding (Legrain and Choulika, 1990). Prp22 protein is 
known to act in the release of mature rnRNA from the spliceosome (Company et a!, 
1991) Prp26 has been shown to be an enzyme which debranches the lariat intron 
(Chapman and Boeke, 1991), an essential step in the degradation and recycling of 
splicing machinery. 
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Prp5 and 28 proteins are members of the DEAD-box family of putative ATP-dependent 
RNA helicases. Brr2 is also known as S1t22 and Yerl72c and is a member of the 
DEXH-box subfamily. 
1.7 Spliceosome assembly and splice-site selection. 
Spliceosomes are known to be formed by the ordered assembly of snRNPs on to the 
pre-message. The first known step in spliceosome assembly is the binding of the U1 
snRNP to the pre-mRNA (Mount et al, 1983). Experiments using RNaseTl in vitro 
showed that the UI snRNP was bound to the 5' splice-site. This agreed with proposed 
base-pairing interactions based on sequence analysis of the 5' splice site and UI snRNA 
(Lerner et al, 1980). 
It was subsequently shown that mutations in the UI snRNA could suppress some 
mutations in the 5' splice-site by restoring the base-pairing interactions (Seraphin et al, 
1988). As the restoration of base-pairing does not always suppress 5' splice-site 
mutations, it is thought that the actual sequence has another function as well as the base-
pairing, and some proofreading mechanism is involved to prevent the aberrantly spliced 
transcript going through step 2 (Siliciano and Guthrie, 1988). 
It has been shown in fission yeast that Ui snRNA base-pairs with both 5' and 3' splice-
sites (Reich et al, 1992). The polypyrimidine tract at the 3' end of the intron is thought 
to be recognised by Ui which then binds to both the splice sites. Interaction of Ui 
snRNA with the 3' splice-site has been shown by making mutant 3' splice-sites, and 
restoring splicing by making compensatory base-changes in Ui. The binding of Ui to 
both splice sites is essential for the subsequent binding of U2. 
It was demonstrated using -g1obin in a mammalian in vitro system that the binding of 
UI snRNP is an important stage early in the formation of the spliceosome. The 
apparent absence of Ui snRNP in early splicing complexes is most likely explained by 
the use of high salt concentrations and heparin in experimental conditions, which is 
shown to disrupt the U  snRNP/pre-mRNA interaction (Bindereif and Green, 1987). 
The binding of the U2 snRNP to the branchpoint region of the pre-mRNA is the next 
stage of spliceosome assembly and the first ATP-dependent step of splicing (Parker et 
al, 1987). This was shown by using mutant yeast branchpoint sequences and looking for 
restoration of splicing by suppressor mutations in the 5' end of the U2 snRNA. Similar 
base-pairing of U2 to the branchpoint sequence in mammalian systems has also been 
demonstrated (Wu and Manley, 1989; Zhuang and Weiner, 1989). 
Recent research provides evidence to support the model in which the base-pairing 
between the U2 snRNA and the conserved branchpoint sequence results in the branch 
adenosine residue being "bulged" out making it accessible for the transesterification 
reaction (Query et al, 1994). 
Of all snRNPs, the U6 snRNP of yeast has the highest homology with its mammalian 
counterpart (Brow and Guthrie, 1988). It has been demonstrated to be associated with 
the U4 snRNP via base-pairing interactions between their respective snRNAs. 
Mutations in the U4 snRNA can be suppressed by making mutations in U6 snRNA 
which restores the base-pairing between the U4 and U6 snRNAs (Shannon and Guthrie, 
1991). When extragenic suppressors of U4 snRNA mutations were isolated, it was 
found that dominant suppressor mutations were mutations in the U6 snRNA, and other 
recessive mutations were allelic with PRP24. Using anti-Prp24 antisera, it was shown 
by immunoprecipitation that the U6 snRNP was associated with Prp24 protein in wild-
type cell extracts. In mutants where the U4/U6 base-pairing is disrupted, Prp24 protein 
co-precipitates with the U4/U6 snRNP. It is proposed that Prp24/U41U6 is normally a 
transient complex in spliceosome formation and/or dissociation (Ghetti et a!, 1995), 
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Figure 1.2. Splicing factors in the yeast pre-mRNA splicing pathway. 
Figure 1.2: This diagram shows the proposed spliceosome assembly pathway showing 
associations of snRNPs with the mRNA. The proposed action points and associations for 
some of the Prp proteins and other trans-acting factors are indicated. 
In mutants where the base-pairing is disrupted, Prp24 stays in association with U4 and 
U6. The U4/U6 complex forms an association with the U5 snRNP to make a tri-snRNP 
complex before joining the spliceosome (Cheng and Abelson, 1987; Lossky et al, 1987; 
Seraphin eta!, 1991). 
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Prior to the first chemical step of splicing, the U4/U6 snRNA interaction is dissociated 
leaving U6 snRNA free to base-pair with the U2 snRNA. The helices formed between 
the U2 and U6 snRNAs are thought to be the basis of formation of the active site of the 
spliceosome (Madhani and Guthrie, 1992; McPheeters and Abelson, 1992; Madhani and 
Guthrie, 1994). 
Newman and Norman (199 1) looked for extragenic suppressors of a G 1-A mutation at 
the 5' splice site. One such suppressor was isolated which was discovered to be the gene 
for U5 snRNA. The suppressor mutation was identified as a single nucleotide change in 
a conserved sequence encoding a single-stranded loop in the U5 secondary structure. 
This mutant was found to specifically suppress only mutations of GI by cleaving the 
pre-mRNA 12 nucleotides upstream of the normal 5' splice-site. It is proposed that U5 
normally prevents aberrantly cut mRNAs going through step 2, thus is important for 
splice-site fidelity. 
It is now known that the conserved loop of the U5 snRNA base-pairs with nucleotides 
upstream of the 5' splice-site (Newman and Norman, 1992). At least in certain 
circumstances, it is the location of this base-pairing that determines the cleavage site. In 
order to allow processing of aberrantly-cut pre-mRNA5 through step 2, the mutant U5 
loop must also be near the 3' splice site before or during step 2. U5 snRNA has been 
shown to bind to two nucleotides of exon 2. U  snRNA is also required to bind to the 
normal 5' splice site for the aberrant cleavage event to occur. 
1.8 DEAD/H box Droteins. 
Some Prp proteins, such as PrpS and Prp28, are members of the DEAD box family of 
RNA-dependent ATPases, where DEAD is a peptide sequence of Asp-Glu-Ala-Asp 
residues (Linder et a!, 1989; Dalbadie-McFarland and Abelson 1990; Strauss and 
Guthrie, 1991). The proposed protein sequences show several motifs, all of which are 
present in ATP-dependent RNA helicases of which the prototype is eIF4-A, a translation 
initiation factor. (Linder et a!, 1989). Other Prp proteins, Prp2, Prp16 and Prp22, (Chen 
and Lin, 1990; Burgess et a!, 1990, Company et a!, 1991) are members of the DEAH 
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subfamily where the second Asp residue is replaced by His. Some residues in the other 
conserved motifs in this class of proteins are also different to those in the DEAD-box 
proteins. 
The consensus sequences of the major conserved motifs are shown below. 
Figure 1.3. DEAD and DEAH-box protein consensus sequences. 
DEAD Family (eg eIF4A) 
ATPase A motif 	ATPase B motif  
NH2H AXXXXGKT h-H DEAD J I SAT I RRIGRXXR[ -  COOH 
	
96-131 	27-51 	140-162 
DEA.H Family (Prp2, Prpl6 and Prp22) 
NH2HGXXXXGKTHHDEAHI ISATI QRIGRXGRCOOH 
89-92 	28 	163-174 
The AXXXXGKT box is known as the ATPase A motif, with the DEAD box being the 
ATPase B motif (Linder et al, 1989). Mutational analysis in eIF4-A has shown these 
two conserved sequences to be important in ATP binding and hydrolysis, with 
GXXXXGKT having a higher rate of ATP hydrolysis than AXXXXGKT (Pause and 
Sonenberg, 1992). 
Mutations in the DEAD and SAT motifs (to EEAD and AAA respectively) have been 
shown to uncouple ATPase activity from RNA helicase activity in eIF4-A. ATPase 
activity either stayed the same or increased over the wild-type in EEAD and AAA 
respectively. These mutants can still bind to ATP although no RNA unwinding activity 
was detectable (Pause and Sonenberg, 1992). 
Evidence for dynamic RNA-RNA interactions in spliceosomes (reviewed in Moore et al 
1993 and Madhani and Guthrie, 1994) strongly suggests important roles for helicases in 
snRNA rearrangements which occur during splicing. Proposed roles include initiating 
and monitoring conformational changes within the spliceosome (Wassarman and Steitz, 
12 
1991), processes which would account for some of the use of ATP during the course of 
the splicing reaction. 
PRP2, PRPI6 and PRP22 are members of the DEAH-box (or DEXH-box) subfamily. 
Their consensus sequences differ in several places from the DEAD-box prototype. 
These three proteins share very similar sequences in the conserved central region, with 
55% identity and 75% similarity. Prp16 and Prp2 proteins both have a transient 
interaction with the spliceosome, Prp2 acting at step 1 and Prpl6 at step 2. 
The sequences related to ATP binding and/or hydrolysis may explain the need for ATP 
hydrolysis for splicing. The many dynamic RNA-RNA interactions which occur 
throughout the splicing process demonstrate the need for RNA helicase or unwindase 
activity in the assembly and disassembly of spliceosomes. 
As mentioned in section 1.7, interactions take place between snRNAs and the pre-
mRNA, such as between Ui snRNA and the 5' splice site. U2 base-pairs with the 
conserved branchpoint region on either side of the branch A nucleotide, which is 
unpaired and bulged out leaving it accessible to the first G residue of the 5' splice site 
(Query et al, 1994). There are also associations between snRNAs, for example the 
interaction between U4 and U6, which is dissociated to allow U6 to form helices with 
the U2 snRNA. There is evidence which supports the theory that U4 maintains U6 in an 
inactive state until it is required by the splicing machinery, whereby U4 is dissociated 
leaving U6 free to associate with U2. Genetic evidence suggests that the Prpl6 protein 
interacts with the U2/U6 helix (Madhani and Guthrie, 1994b). Intramolecular helices 
are a key feature of the secondary structure of the snRNAs. It is conceivable that many 
of these interactions, which change throughout the splicing reaction, require the action 
of helicases. Notably, each stage of spliceosome assembly and step of splicing requires 
both ATP and a DEAD/H-box protein (see figure 1.2). 
1.9 PRPJ6 
An A to C mutation of the branch nucleotide in the ACT] intron has been shown to 
inhibit splicing (Vijayraghaven et al, 1986). PRP16 was first identified through 
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isolation of prpl6-1 as a suppressor of this mutation which restored splicing activity 
(Couto et a!, 1987). An intron-containing ACT]-HIS4 fusion was integrated at the 
deleted HIS4 locus on the genome of a diploid yeast strain. These diploids were used as 
a reporter strain for suppressor mutants. Integrants were tested for growth on Histidinol 
(Hol), the precursor of histidine on which the product of the HIS4 gene acts. One isolate 
out of 521 tested was found to grow on Ho!. Primer extension and Northern analysis 
suggests that this isolate did indeed use the C nucleotide at the branchpoint for splicing, 
and not a cryptic or alternative branchpoint (Vijayraghavan et al, 1986; Couto et a!, 
1989). Tetrad analysis showed that there was a single locus for the gene, which was 
called prpl6-1. 
This gene was later cloned and sequenced (Burgess et a!, 1990). The sequence showed 
a 1071 amino acid open-reading frame with sequence motifs found in NTP-binding 
proteins. The prpl6-1 mutation was found to be a point mutation encoding a single Tyr 
to Asp change near the conserved ATPase A site. 
Immunodepletion of splicing extracts using antibodies specific to Prp 16 protein showed 
that spliceosome assembly and the first step of splicing did not require Prp16 (Schwer 
and Guthrie, 1991). This was also shown to be the case for prp23-1, now known to be 
encoded by an allele of PRP16, prpl6-2. 
The immunodepleted PRP16 extracts could be complemented by adding a partially-
purified Prp16 fraction. The dynamics of this complementation demonstrated that the 
spliceosome was not disassembled and reassembled on addition of Prpl6 protein before 
splicing could take place. 
PRPI6 was then epitope-tagged by adding a sequence to the C terminus. This enabled 
purification of the Prp 16 protein using a monoclonal antibody specific to the epitope 
tag. The purified protein was shown to complement mutant prpl6-2 extracts. RNA-
dependent ATPase activity was demonstrated in the purified protein. It was then shown 
by immunoprecipitation that the Prp16 protein gets stuck in the spliceosome in the 
absence of ATP. Epitope-tagged, purified prpl 6-1 has subsequently been shown to have 
reduced ATPase activity (Schwer and Guthrie, 1992). This leads to prpl6-1 getting 
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stuck in the spliceosome even in the presence of ATP. Pre-formed spliceosomes 
containing prpi6-1 protein cannot be complemented by the subsequent addition of 
Prp16 at low temperatures. This can account for the cold-sensitive dominant-negative 
growth defect shown by cells heterozygous for PRPI61prpl6-1. 
The suggestion that Prp 16 protein has a proofreading role in step 2 of splicing led to the 
proposal of a mechanism for suppression of branchpoint mutants (Burgess and Guthrie, 
1993). When prp 16-I gets stuck in the spliceosome, the reduced rate of ATP hydrolysis 
is presumed to lower the fidelity of the proofreading mechanism, allowing the mutant 
branch nucleotide to be used. 
Prp16 protein has been shown to induce a conformational change of the spliceosome 
(Schwer and Guthrie, 1992). It has also been demonstrated that Prp16 can be 
crosslinked to the 3' splice site of pre-thRNA in spliceosomes. 
A search for suppressors of dominant-negative cold-sensitive PRP16 mutants isolated 
mutants of the U6 snRNA (Madhani and Guthrie, 1994). Alleles of PRP16 are 
synthetically lethal with alleles of PRP1 7 and SLU7 (Frank et al, 1992), which suggests 
that these factors interact around step two of splicing. It has been suggested that Prp16 
protein may act as a molecular switch initiating a conformational change of the 
spliceosome which takes place at step 2 of splicing. This action may be regulated by the 
rate of ATP hydrolysis by Prp16 or by possible helicase activity regulating changing 
RNA/RNA interactions. 
1.10 PRP2 
The PRP2 gene was first cloned and sequenced in this lab (Lee et a!, 1984). The gene 
was cloned by transforming a temperature-sensitive (ts) prp2-1 strain with a YEP24-
based plasmid library, and selecting for transformants at the non-permissive 
temperature, 36°C. One transformant was isolated and the plasmid extracted. This 
plasmid was found on transformation to rescue the ts phenotype of four different prp2-1 
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strains. PRP2 was shown to be a single gene with a 3.2kb EcoRI-BamHI fragment 
essential for the rescue of the ts phenotype. 
Figure 1.4. Map of PRP2 showing unique restriction sites. 
EcoRI 	 Hindu 	XbaI 	 Pvufl 	Saul 	BamHl 
200 	817 	 778 	 582 	 579 	I 375 
PRP2 	 ORF 
promotor  
H GXXXXGKT H-H DEAH H-H SAT 
Figure 1.4 1.4 Restriction map of PRP2 including the 200bp promoter region and the 3kb 
coding region. Restriction fragment sizes are shown in bp. Conserved protein motifs 
encoded by the HindIII-XbaI fragment are indicated below. 
Immunoprecipitation using Prp2-specific antisera has shown Prp2 protein to be 
associated with the spliceosome before and during step 1 of splicing (King and Beggs, 
1990). This association was found not to happen in the presence of a mutant 
branchpoint or 5' splice site, or in the absence of ATP. When prp2-1 mutant extracts 
were heat-inactivated, spliceosomes could no longer be precipitated by anti-Prp2 
antisera, suggesting that heat-inactivated prp2-1 protein is not associated with the 
spliceosome. 
As mentioned above, Prp2 is a member of the DEAH subfamily of DEAD-box proteins 
(Company et al, 1991). It shares extensive sequence homology with Prp16 and Prp22 
over their central regions, with 55% identity and 75% similarity, although each protein 
has differing NH2- and COOH- termini. Prp16 and Prp2 proteins both have a transient 
interaction with the spliceosome, Prp2 acting at step 1 and Prp16 at step 2. Prp22 
protein has recently been shown to have RNA helicase activity in vitro (Wagner et al, 
1996). This is the first example of helicase activity known in this group of proteins. 
The presence of sequence motifs common to both Prp2 and Prp16 has lead to 
speculation that these proteins carry out a similar role in the splicing pathway, with 
different specificities encoded by the different 5' and 3' sequences of these genes. As a 
proofreading role has been suggested for PRP16, it is exciting to speculate that PRP2 
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may have a similar role at an earlier step of splicing. Genetic evidence suggests that 
Prp2 protein interacts with at least one other protein factor, Spp2, during step one of 
splicing (Last et al, 1987; Roy et al, 1995). 
The interaction between Prp2 protein and the spliceosome is of a transient nature. In 
order to facilitate the study of this interaction, dominant negative mutants have been 
generated which enter the spliceosome and form a stable association preventing splicing 
from taking place (Plumpton et al, 1994; E. Flinn, 1994). Random dominant negative 
mutants were generated (Plumpton et al, 1994) which, when sequenced, all contained a 
mutation which resulted in a serine to leucine change in the SAT box, which in eIF4A is 
required for RNA unwinding activity. This mutant, PRP2 th , inhibited growth when 
overexpressed from a conditional promoter in a wild-type strain. In vitro analysis of this 
mutant showed inhibition of splicing and the stalling of splicing complexes. 
Immunoprecipitation experiments with anti-Prp2 antibodies demonstrated that the 
normally transient interaction between Prp2 and the spliceosome was to some extent 
stabilised by the dominant negative mutant, which, unlike the wild-type Prp2 protein, 
remained associated with the spliceosome in the presence of ATP. Assays carried out 
with purified p2dnl  protein demonstrated that Prp2 
d, 1  had around 40% of the RNA-
stimulated ATPase activity of the wild-type protein. 
UV crosslinking experiments were carried out in an in vitro system using Prp2 
(Teigelkamp et al, 1994). These experiments showed that the Prp2 protein directly 
contacted the pre-mRNA. This reaction was independent of an intact 3' splice site, but 
was shown to require a pre-mRNA capable of formation into an intact spliceosome. 
Experiments using an ATP-depleted system and purified wild-type Prp2 protein showed 
that the results obtained for Prp2hI  were also true for wild-type Prp2 protein. 
Subsequent dominant negative mutants of PRP2 were generated by site directed 
mutagenesis of the GKT-box (E. Flinn, 1994). Mutations resulting in GKT to GKN 
(Prp2° ) and AKT (Prp2 T) substitutions were made and found to be dominant 
negative. The Prp2 GKN  mutant was found to be similar to Prp2, forming a stable 
association with the spliceosome. In contrast to Prp2thhl ,  ATPase activity in both the 
Prp2c' KN and p2AKT  mutants was found to be negligible. The dominant negative 
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phenotype of the prpT  mutant was also different, exhibiting dominance upon 
overexpression only at 30°C and under. A stable association between 
p2AKT  and the 
spliceosome has never been demonstrated. However, p2AKT  has been demonstrated to 
bind to poly(U) in vitro (M. McGarvey, unpublished results). 
EI 
1.11 RAS 
One dominant negative mutation of PRP2 was inspired by a mutation made in RAS 
which gave a dominant negative phenotype. Both mammalian H-ras and yeast Rasi and 
Ras2 proteins contain similar sequences to those conserved between Prp2, Prp16 and 
Prp22. Mutagenesis resulted in a GKT to AKT change (Powers et a!, 1989). 
Figure 1.5. The GTPase cycle. 
Figure 1.5. G represents the GTPase protein, GAP is the GTPase activating protein, and 
GNRP is the guanine nucleotide release protein. The GNRP serves to stabilise the transient 
nucleotide-free form of the GTPase. 
This mutation is thought to confer dominant negative activity on Ras by stabilising the 
interaction between Ras2 and the nucleotide exchange factor, Cdc25. The Cdc25 
protein acts upstream of Ras2 which exchanges GDP for GTP thus activiating Ras 
(Broek et a!, 1987). 
The dominant mutation in Ras2 is believed to stabilise the normally transient interaction 
between Ras2 and Cdc25 which occurs around the time of exchange of GDP for GTP by 
Ras2. This stabilisation results in free Cdc25 protein being depleted. It has been 
suggested that a similar mutation in PRP2, PRP2AKT, results in the stabilisation of an 
interaction between Prp2 protein and a possible nucleotide exchange factor (E. Flinn, 
1994). 
19 
1.12 This thesis. 
The aim of this thesis was to investigate the role in splicing of conserved sequences in 
the Prp2 protein by mutagenesis. 
The first sequence to be investigated was the zinc finger-like motif. A strategy was 
developed to mutagenise key amino acid residues involved in zinc finger function. 
Deletion analysis of three dominant-negative alleles of PRP2 was carried out in order to 
map RNA-binding activity. This led to a suggestion that the Prp2 protein may interact 
with a factor involved in splicing complex formation. An attempt was made to 
investigate this hypothesis. 
Finally, the similarity between PRP2 and PRP16 led to the investigation of a possible 
proofreading role for Prp2 protein in splicing. 
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Chapter two. 
Materials and methods. 
2.1 Materials, 
2.1.1 Suppliers of laboratory reagents. 
Standard laboratory reagents were purchased from Sigma, Fisons and BDH. 
Restriction endonucleases and nucleic acid modifying enzymes were purchased from 
Boehringer, New England Biolabs, Gibco BRL and Pharmacia. 
Deoxyribonucleotides and ribonucleotides were purchased from Pharmacia and Sigma. 
Radiochemicals were purchased from Amersham International. 
Acrylamide was purchased from Appligene and Scotlab. 
Media reagents were purchased from Difco, Oxoid, Sigma and Fisons. 
2.1.2 Growth Media 
Unless otherwise stated quantities are for I litre volume. Solutions were autoclaved 
(section 2.2.2) and stored at room temperature. Antibiotics and amino acids were stored 
as sterile concentrated stocks and were added to media immediately prior to use. For 
plates, Oxoid No.1 agar was added to 2% (w/v) before autoclaving. 
2.1.2.1 E.coli media. 
Luria-Bertani medium (LB): 
lOg peptone, 5g yeast extract, lOg NaCl, adjusted to pH7.2 with NaOH. 
0. lgfl ampicillin was added as necessary (LB-amp). 
M9 medium: 
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6g Na2HPO4, 3g KH2PO4, 0.5g NaC1, ig KH4C1. 0.25g MgSO4.7H20, 2g glucose. 
20mg amino acids and other nutritional requirements were added after autoclaving. 
2XYT: 
lOg peptone, lOg yeast extract, 5g NaCl. 
BBL Bottom plates: 
lOg trypticase, 5g NaCl, lOg agar. 
lOg trypticase, 5g NaCl, 6.5g agar. 
2.1.2.2 Yeast Media. 
YPDA: 
lOg yeast extract, lOg peptone, 20g glucose, 20mg adenine sulphate. 
YMGIu: 
6.7g yeast nitrogen base without amino acids, 20g glucose, supplemented with 20mg 
amino acids as required. 
YMGa1IRaf: 
6.7g yeast nitrogen base without amino acids, 20g galactose, 20g raffinose, 
supplemented with 20mg amino acids as required. 
YMG1uCas, YMGalIRafCas: 
YMG1u or YMGa1IRaf plus lOg vitamin assay casaminoacids. 20mg adenine, 
tryptophan and uracil were added after autoclaving as required. 
Pre-sporulation: 
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8g yeast extract, 3g tryptone, lOOg glucose. 
Sporulation: 
lOg potassium acetate, I  yeast extract, 0.5g glucose, 2mg required amino acid. 
YlviGlyLacCas: 
6.7g yeast nitrogen base without amino acids and lOg vitamin assay casaminoacids in 
800m1 H20. After autoclaving, lOOmI sterile 20% lactic acid pH5.7 and lOOmI sterile 
20% glycerol were added. For galactose induction, galactose was added to 2% (w/v). 
5-FOA: 
6.7g yeast nitrogen base without amino acids, 20g glucose, 2g vitamin assay 
casaminoacids, 50mg uracil, 2g agar in 500m1 H 20, autoclaved. ig 5-fluoroorotic acid 
dissolved in 500m1 H20, filter sterilised and added to the autoclaved mixture before 
pouring into Petri dishes. 
Synthetic Complete (SC): 
20g Glucose or Galactose plus the following: 
Supplement Final concentration 
(mg/1) 
Stock per lOOml Amount of stock 
per litre 
Adenine sulphate 20 200mg a 10 
Uracil 20 200mg a 10 
L-Tryptophan 20 1  2 
L-Histidine-HC1 20 1  2 
L-Arginine-HC1 20 ig 2 
L-Methionine 20 1  2 
L-Tyrosine 30 200mg 15 
L-Leucine 30 ig 3 
L-Isoleucine 30 lg 3 
L-Lysine-HC1 30 ig 3 
L-Phenylalanine 50 ig a 5 
L-Glutamic acid 100 ig a 10 
L-Aspartic acid 100 ig a,b 10 
L-Valine 150  5 
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200 4g a,b 5 LL--Threonine Serine 400 8g 5 
stored at room temperature (other stocks stored at 4°C) 
added to media after autoclaving. 
2.1.3 Bacterial strains. 
Table 2.1 E.coli strains 
Strain Genotype Description Reference/origin 
NM522 A(lac-proAB), Strain for propagating Gough and Murray, 
E(hsdMS-mcrB)5, supE, plasmids 	and 1983 
thi-1, 	F'[laclq, 	lacZzi phagemids 
M15, proAB]  
NM547 dam-. 	ara, 	B], 	iA(lac- Methylation 	minus N. Murray 
pro), rpsL, SmR strain for propagating 
plasmids 	with 
methylation-sensitive 
restriction sites.  
JDBI dam-. 	ara, 	B], 	L(lac- Methylation 	minus J. Beggs, this lab. 
pro), rpsL, SmR F[lacJQ, strain for propagating 




BMH71- 6('lac,pro), 	supE, 	thi, Repair-deficient strain Kramer et al, 1984 
18mutL mutL, F' (proAB, lad, for 	site-directed 
lacZiM15). mutagenesis.  
BW313 HfrKL16 	P0/45 	lysA Repair-deficient strain Amersham 
(61-62), duti, ung], thi- for 	site-directed International 
1, recA, SpoT] mutagenesis. I 
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2.1.4 Yeast strains. 
Table 2.2 Yeast strains. 
Strain Genotype Description Reference/origin 
S1150-2B a, ura3-52, leu2 -3,-112, trpl-289 general 	strain 	for Wellcome 
GAL+. transformation and 
splicing extracts  
BJ2412 a, ga12, leu2, pep3-4, prb]-]1,prc- protease 	deficient E. 	Jones 
407,, trp], ura3-52. strain for splicing (Pittsburgh) 
extracts  
DJy85 a/(x, 	prp2-11prp2-1, 	ura3/ura3, diploid D. Jamieson (this 
adel/ADE], 	ade2/ade2, homozygous 	for lab.) 
trpl/TRP], his3/HIS3, tyrl/TYR1, the 	temperature- 
lys2-8011LYS2, can]/CAN]. sensitive 	prp2-1 
allele 
DJy36 a, ura3-2152, ade2, prp2-1. haploid D. Jamieson (this 
temperature - lab.) 
sensitive 	prp2-1 
strain  
EFy1 a/a, 	ura3-521ura3-52, 	his3-L diploid 	with 	one E.Flinn 	(PhD 
2001his3zil, 	ade21010C/ADE2, genomic copy of thesis, this lab.) 
lys2-801/LYS2, 	rrpl-41/trpl-289, PRP2 disrupted by 
LEU21leu2-3, 112, HIS3. 
PRP21PRP2: :HIS3.  
51 a, lys2, his3, ura3, trp], leu2, ade, cup] strain for 3- Guthrie 	lab. 
GAL, cup]. galacosidase (UCSF) 
assays  
46 a lys2, his3, ura3, trp], leu2, ade, cup] strain for 3- Guthrie 	lab. 
GAL, cup]. galacosidase (UCSF) 
assays  
2.1.5 DNA constructs. 
Table 2.3 DNA constructs. 
Construct Description Reference/origin 




ARS, CEN, URA3 vector 
containing the GAL] 
promoter on a 0.8kb EcoRI-
BamHI fragment  
Johnston 	and 	Davies, 
(1984) 
pBMPRP2 GAL inducible PRP2 King and Beggs, 1990 
pBMPRP2HiS Polyhistidine tagged GAL 
PRP2  
Plumpton et al, (1994) 
pBMPRP2LATHiS Polyhistidine tagged GAL 
PRP2LA THis  
Plumpton et al, (1994) 
pBMPRP2AKTHiS Polyhistidine tagged GAL 
PRP2AKTHis  
E.Flinn (this lab.) 
pEF2 PRP2::URA3 E.Flinn (this lab.) 
M13P2C2 M13 phage PRP21C2 E. Whittaker, J. Morran 
(this lab.) 
pFL39 2p. TRP1 vector Bonneaud et al, (199 1) 
pRS315 Sikorski 	and 	Heiter, 
(1989) 
pSB1 2p.prpl6-1 Burgess 	and 	Guthrie, 
(1993) 
pBS36 ACTJ/C UP] mutant fusion 
pSB47 ACTJ/CUP] mutant fusion 
pSB48 ACT1/CUP] mutant fusion 
pSB49 ACT1/CUP] mutant fusion 
pSB50 ACT] IC UP] mutant fusion 
pGlOO ACT1/CUP] mutant fusion Lesser 	and 	Guthrie, 
(1992) 
pG14 ACTJ/CUP] 	wild 	type 
fusion  
pG24 ACT]/CUP] 	wild 	type 
fusion  
pGlPRP16epit 2ji 	PRP16 	with 	PGJ 
promoter  
'I 
pYAHB2/Al ACT]/lacZ mutant fusion Vijayraghaven 	et 	al, 
(1986) 
pYAHB2/WT ACT]/lacZ wild type fusion 
pTZ18 E.coli phagemid Pharmacia 
pTZ19 E.coli phagemid Pharmacia 
pT7/rp28s Template 	for 	in 	vitro 
transcription of rp28  
M. Lossky (this lab.) 
x;i 
2.1.6 Antisera. 
Table 2.4 Antisera. 
Antiserum Antigen Origin 
Anti-54 Fusion 	2.3 	protein. 	(see 
figure 2. 1).  
King and Beggs (1990) 
Anti-55 Fusion 2.3 protein. D.King (this lab) 
Anti-140 Fusion 	2.5 	protein 	(see 
figure 2.1).  
D.King (this lab) 
Figure 2.1. Anti-Prp2 antibodies used in this thesis. 
EcoRI 	Hincffll 	XbaI 	Pvull 	 BamHI 
PRP2 
2.3 	 Regions present in 
3-ga1actosidase-Prp2 
AflI HindHI 2.5 PvuH fusion proteins against 
which antibodies were 
raised. 
2.1.7 Oligodeoxyribonucleotides. 
All oligodeoxyribonucleotides were synthesised by the Oswel DNA Service (Edinburgh 
University). 
Table 2.5 Oligodeoxyribonucleotides 
Oligo Description Sequence (5'-3') 
036A Universal Primer CCCAGTCACGACGTT 
413G Reverse primer AACGTCGTGACTGGG 
163H His-Leu in MBF of Prp2 by 
PCR  
TACAGCTGCTACGCTCGAAC 
164H Cys4-Ser in MBF of Prp2 by 
PCR 	 JATCTCAAGG 
TACAGCTGCTACGCACGAACA 
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168H PRP2 PCR oligo in reverse 
orientation to 163-165H  
GCGGATCCAAACAATCTC 
029A PRP2 primer at ntl6lO GATTATAACTCCTATA 
028A PRP2 primer at ntl 196 TCTTACAGATTCCAAA 
131K PRP2 primer at nt2339 CCAATGGAGAAACTC 
027A PRP2 primer at nt1970 TACGGTGTTATTAfl'A 
448K Cys2-Ser in MBF of Prp2 TTTCCTTCTGAACCTGA 
026A Cys2-Tyr in MBF of Prp2 TTTCCTTATGAACCTGA 
882F His-Cys in MBF of Prp2 GCTGCTACGTGCGAACAATGT 
A171 T-Val in GKT box of Prp2 CCAGAACCGACTTCACCC 
883F Cysi-Tyr 	in 	MBF 	of Prp2 
(replaces oligo 025A)  
ATGATGTACGAGTTTCC 
10K Makes Tyr-Asp change in Prp2 
(homologous to prpl6-1 
mutation)  
GTTACCCCAAGATTTGGTAG 
132K PRP2 primer at nt2533 GATGCTTCATCAGCGGG 
304L PRP2 primer at nt GGGCAAGAAGAAATTG 
JB1 Self 	anneals 	to 	form 	blunt 
ended linker 	with 	diagnostic  
Cal site  
CTAATCGATTAG 
















2.1.8 Size markers. 
Size markers for agarose gel electophoresis were Lambda DNA (Gibco BRL) digested 
with Hindffi restriction endonuclease, and 1kb ladder (Gibco BRL). 




1M NaPO4 1M NaH2PO4 and 1M Na2HPO4 at 3:2 (v/v) to pH7. 
lox PBS 	15mM NaH2PO4, 80mM Na2HPO4 , 1.5M NaCl pH7.2 
lox TAB 	0.4m Tris-acetate pH7.5, 20niM EDTA. 
lox TB 	0.9M Tris-borate pH8.3. 
iox TBE 	0.9M Tris-borate pH8.3, 20mM EDTA. 
lox TBS 	0.5M Tris-HC1, 1.5M NaC1 pH7.5. 
iox TE 	10mM Tris-HC1, 1mM EDTA pH8.0. 
20x SSC 	3M NaCl, 0.3M tn-sodium citrate p117.0. 
2.2 General Methods. 
2.2.1 General guidelines. 
Unless otherwise stated all procedures were carried out at room temperature. For small 
scale procedures sterile 1 .5ml polypropylene microcentnifuge tubes (Treff) were used, 
larger scale procedures being carried out in 15m1 and 30m1 sterile Corex tubes, lOmi 
Sterilin tubes and 50m1 Greiner tubes. 1 to 41 cell cultures were harvested in 250m1 or 
500m1 Nalgene polycarbonate or polyallomer centrifuge bottles. 
Centrifugation of volumes greater than 50m1 was carried out in a Sorvall Super Speed 
centrifuge using either a GS-A or GS-3 rotor at 5,000 rpm. Volumes between 1.5 and 
50m1 were centrifuged in an SS34 rotor at speeds between 10,000 and 17,000 rpm or in 
an EEC Centra-4X bench top centrifuge at 4,000 rpm. High speed centrifugation was 
performed in a Sorvall OTD ultracentrifuge. Volumes of 1 .5ml or less were centrifuged 
in an Eppendorf centrifuge at 14,000 rpm. 
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2.2.2 Sterilisation procedures. 
When necessary, plastics such as microcentrifuge tubes and pipette tips, and solutions 
were sterilised by autoclaving for 20 minutes at 120°C and 15 psi. Solutions not 
suitable for autoclaving and small volumes were sterilised by filtration through a 
disposable Acrodisc syringe filter (0.45 gm pore size, Gelman Sciences). 
Sterile and RNase-free glassware was dry-sterilised by baking at 250°C for 16h. 
2.2.3 Deionisation of solutions. 
Formamide and acrylamide solutions were deionised by mixing with 0.1-0.2 volumes of 
analytical grade mixed bed resin (20-50 mesh, Bio-Rad) for 30 minutes. The resin was 
removed by filtration through Whatman No.1 filter paper. Acrylamide was stored at 4°C 
and formamide at -20°C. 
2.2.4 Photography. 
Photographs of agarose gels stained with I jig/mi ethidium bromide were taken using a 
UVP electronic imaging system during visualisation of the nucleic acid by short wave 
ultraviolet light (254nm) from a UVP transilluminator. Photographs of yeast growing 
on Petri dishes were taken using the same system, using a white lightbox instead of the 
transilluminator. 
2.2.5 Autoradiography. 
[32P] -labelled nucleic acids were detected by exposing pre-flashed X-ray film to the 
subject in a light proof cassette with a calcium-tungstate intensifying screen at -70°C. 
[35S] -labelled DNA was detected by exposure of X-ray film to dried gels at room 
temperature. 
2.3 MICROBIOLOGICAL METHODS. 
2.3.1 Propagation and storage of bacterial strains. 
Growth and storage of E.coli were carried out as in Sambrook et al (1989). 
2.3.2 Preparation of competent E. coli. 
Based on the method of Hanahan (1983). 
I) I OOml of LB was inoculated with 1 ml of a stationary phase culture and grown to 
0D600 0.3-0.7. 
The culture was chilled on ice before cells were harvested in a benchtop centrifuge. 
The cell pellet was resuspended in 50m1 ice-cold 75mM CaC12 and incubated on ice for 
a minimum of 20 mm. 
Cells were pelleted again and resuspended in lOml ice-cold 75m1V1 CaC1 2. These 
were either used immediately or stored at 4°C for up to 48h. 
2.3.3 Transformation of competent E. coli with plasmid DNA. 
Competent cells were aliquoted into 200.tl volumes, DNA added (about 50-10ng 
plasmid or a portion of a ligation) and incubated on ice for a minimum of 20 mm. 
The cells and DNA were heat shocked at 42°C for 2-5 mm. 
lml of LB was added, and the cells incubated at 37°C for lh to allow expression of 
the antibiotic resistance gene. 
The cells were pelleted by spinning in a microcentrifuge and most of the supernatant 
poured off. 
The cells were resuspended in the remaining supernatant and spread onto LB-amp 
plates which were incubated inverted at 37°C overnight. 
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2.3.4 Transfection of competent E. coli with phage DNA. 
DNA (as for transformation) was added to 200pJ aliquots of competent E.coli in 
sterile 3m1 glass test tubes and incubated on ice for a minimum of 20 mm. 
The cells were heat shocked at 42°C for 2-5 mm. and returned to the bench. 
200pi stationary cells and 3m1 cooled (no more than 42 °C) molten BBL top agar was 
added and mixed by inversion. The stationary cells provide a lawn in which plaques 
may form. 
The contents were poured onto a BBL bottom plate. 
When set, the plate was inverted and incubated at 37°C overnight. 
2.3.5 Propagation and storage of yeast. 
Yeast cells were grown and stored as described in Rose et al (1990). 
2.3.6 Sporulation and spore recovery. 
Diploid strains to be sporulated were grown first on presporulation plates for one or two 
days and then on sporulation plates for 3-4 days at 25°C or 30°C. 
Asci were resuspended in spore buffer (1.2M sorbitol, 10mM EDTA, 100mM citric 
acid). 20p0 3-glucuronidase/arylsulphatase (Boehringer) was added to digest the ascus 
walls. After incubation at room temperature for 20 min*,  dissection of asci was carried 
out using a Singer MSM micromanipulator (Singer Instrument Co.), the four haploid 
spores being placed separately in a row on a plate of an appropriate medium. 
The plate was incubated at 25°C or 30°C until the spores grew into colonies (around 3-6 
days). 
*The  digested asci can be stored at 4°C overnight at this stage. 
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2.3.7 Transformation of yeast. 
(Geitz et al, 1992) 
A lOOmi yeast culture was grown in complete medium to 0D600 0.4-0.7. 
Cells were harvested, washed with 20m1 sterile IX TE/IX lithium acetate, and 
resuspended in 250.tl 1X TE/1X lithium acetate. 
I-10pg DNA to be transformed, 5j.il salmon sperm DNA (100mg/mi), and 300j.il 50% 
PEG was added to 50jii aliquots of cells and incubated with agitation at 25°C or 30°C 
for 30 mm. 
Cells were heat shocked at 42°C for 15 mm, then spun down. 
The supernatant was removed and the cells resuspended in 50.tl sterile dH20 before 
being spread on selective medium and incubated at 25°C or 30°C for 2-5 days until 
colonies appeared. 
2.4 Nucleic Acid Methods. 
2.4.1 General methods. 
Many standard DNA and RNA manipulations were carried out either according to 
Sambrook et al (1989) or according to manufacturers instructions. These included 
quantitation of nucleic acids by spectrophotometry, restriction endonuclease digestion of 
DNA, dephosphorylation of DNA, agarose gel electrophoresis of DNA and RNA, 
purification of DNA fragments from agarose gels (Qiaex, Diagen Inc.), and ligation of 
DNA fragments. All DNA was stored in sterile ddH 20 at 4°C, and RNA stored in 
ddH20 at -20°C. Main stocks of oligonucleotides were stored at -70°C with aliquots at - 
20°C. 
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2.4.2 DNA preparations. 
2.4.2.1 Small scale plasmid preparation. 
Based on the method of Birnboim and Doly (1979). 
5m1 LB-amp was inoculated with a single bacterial colony and incubated at 37°C 
with shaking for 5h or overnight. 
1 .5ml of the culture was harvested in a microcentrifuge tube by spinning for 10mm. 
The liquid was discarded and the cell pellet resuspended in 100p 1 solution A and 
incubated at room temperature for 5mm. 
200p1 solution B was added and the lysed cells mixed by inversion. 
15Otl solution C was added, the contents mixed thoroughly by inversion and placed 
on ice for 5mm. 
Cell debris was removed by spinning for 15min and the supernatant transferred to a 
fresh tube. 
The supernatant was extracted once with an equal volume of phenol, once with 
phenol/chloroform/isoamyl alcohol (25:24:1), and once with chloroformlisoamyl 
alcohol (24:1). 
2-3 volumes of absolute ethanol were added to the aqueous phase, mixed well and 
spun at 4°C for 20mm. 
The pellet was washed once with 70% (v/v) ethanol, dried in a vacuum desiccator and 
dissolved in 30jil dH20. 
Buffers. 
A: 50mM glucose, 25mM Tris-HCI pH8.0, 10mM EDTA. 
B: 0.2M NaOH, 1% (wlv) SDS. 
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C: 3M sodium acetate pH5.2. 
2.4.2.2 Large scale plasmid preparation. 
50m1 LB-amp was inoculated with lOpi of a stationary culture and incubated 
overnight with agitation at 37°C. 
The cells were harvested by spinning in a benchtop centrifuge at full speed for 20mm. 
The cells were resuspended in 2m1 solution A and incubated on ice for 5mm. 
4m1 solution B were added, mixed by inversion and incubated on ice for 5mm. 
3m1 solution C were added, mixed well by inversion and incubated on ice for 5mm. 
This was transferred to a 50ml polycarbonate tube and spun for 10min at lokrpm at 4 
°C 
The supernatant was transferred to a 30m1 Corex tube and 1 6ml of ethanol added. 
This was incubated at -20°C for 30min before spinning down the DNA at 4°C at 
lOkrpm for 10mm. 
The pellet was resuspended in 2ml buffer D and extracted once with 2m1 
phenol/chloroform. The aqueous phase was removed and the phenol phase back 
extracted with another 2m1 of buffer D. 
The two aqueous phases were pooled in a I 5ml Corex tube and 8m1 ethanol added 
before incubating at -20°C for 30mm. 
II) The DNA was pelleted at 10K rpm and the pellet resuspended in 400pi TE. 
RNase A was added to a concentration of 0.2j.tg/pi  and incubated at 37°C for 45mm. 
RNase treated DNA was extracted once with phenol, once with phenol/chloroform 
and once with chloroform before 0.1 volumes 3M sodium acetate and 2 volumes ethanol 
were added to precipitate the DNA. 
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14) After incubation at 4°C for 30min and spinning at 4°C for 30mm, the pellet was 
washed with 70% (v/v) ethanol, dried under vacuum and dissolved in 200jtl ddH 20. 
This method routinely yielded 100-200jig DNA. 
Buffers. 
Solutions A, B and C as section 2.4.2.1. 
Solution D: 0. IM sodium acetate pH 5.2, 1 m EDTA, 0.1% (w/v) SDS, 40mM Tris-
HC1 pH 8.0. 
2.4.2.3 Preparation of replicative form (RF) DNA from M13 
As above except: 
Harvested cells were washed with 20m1 STE after step 2. 
STE: 0.1M NaCl, 10mM Tris pH8.0, 1mM EDTA pH8.0 
2.4.2.4 Preparation of single stranded DNA from M13 phage. 
A 1.5m1 culture of NM522 was grown in 2XYT to 0D600 0.3 at 37°C. 
A fresh plaque was picked into the culture of NM522 and grown for 5-6h at 37°C 
with vigourous shaking. 
The cells were pelleted by spinning for 5mm. 
1 m of the supernatant was transferred to a fresh tube. 
150pi PEG/NaCI was added and incubated at room temperature for 20mm. 
The phage were pelleted by spinning for 10mm. (If no pellet was present, the tube 
was discarded.) 
The PEG/NaCI was removed and the pellet resuspended in 10091 T 10E0 , 1 
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8) This was extracted with phenol and precipitated with ethanol before being dried and 
resuspended in 25pJ T 1 0E01. 
Buffers. 
PEG/NaCI: 20% (w/v) PEG 6000,4M NaCl. 
T 10E01 : 10mM Tris pH7.5, 0. 1mM EDTA. 
2.4.2.5 Preparation of single stranded DNA from pTZ phagemids. 
1 .5m1 2XYT was inoculated with 30111 of a stationary culture of E. coli transformed 
with the recombinant pTZ, and grown at 37°C with vigorous shaking for 30mm. 
4.5111 M13K07 helper phage were added and the culture grown for a further 5-6h at 
37°C with vigorous shaking. 
The cells were pelleted and the supernatant transferred to a fresl 3i tube. 
1 5Ojil PEGINaCI was added and incubated at room temperature for 20mm. 
Phage were pelleted by spinning for 10mm. The supernatant was removed and the 
tubes spun again and residual supernatant removed. 
The phage pellet was resuspended in lOOjil T 10E0 . 1 and extracted once with 
phenol/chloroform. 
The DNA was precipitated by adding 0.1 volume 3M sodium acetate pH 5.3 and 2 
volumes ethanol. 
After precipitation the pellet was dried under vacuum and resuspended in 25111 
T 10E0. 1 . 
Buffers: as section 2.4.2.3 
(Ml 3K07 was prepared as recommended by the supplier (Pharmacia)) 
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2.4.3 DNA sequencing. 
All sequencing reactions were carried out using the Sequenase version 2.0 kit 
(USB/Amersham) according to the instructions provided. Templates for the reactions 
were single stranded preparations of recombinant pTZ phagemids (7tl of preparation) or 
Ml 3 phage (4tl of preparation). Products of sequencing reactions were run on 6% 
(w/v) acrylamide/7M urea denaturing gels in IXTB buffer, fixed in 10% (v/v) methanol 
10% (v/v) acetic acid for 20min and dried on a vacuum gel drier. 
2.4.4 Site-directed mutagenesis. 
2.4.4.1 Site-directed mutagenesis based on the method of Kunkel etal(1987). 
Generation of uracil -containing template DNA: 
Double stranded recombinant pTZ DNA was transformed into the duf, ung E.coli strain 
BW3 13, and a single transformant grown overnight. This culture was used to prepare 
single stranded template DNA as described in section 2.4.2.4. BW313 lacks the 
dUTPase responsible for metabolising dUTP so DNA synthesis proceeds with dUTP. 
Kinasing the synthetic oligodeoxyribonucleotide: 
The oligodeoxyribonucleotide carrying the desired mutation (see table 2.5) was 
phosphorylated as follows: 200pmol oligodeoxyribonucleotide, 3pi 1M Tris-HCI pH8.0, 
1.5j.tl 0.1M DTT, 1.0j.il 0.2M M902, 1 .091  10mM ATP and 5 units T4 polynucleotide 
kinase, combined in a 30pi final volume. This was incubated at 37°C for I h before 
inactivating the enzyme at 65°C for 30mm. 
Annealing the synthetic oligodeoxyribonucleotide to template DNA: 
0.5pmol template DNA, 5pmol kinased oligo and 2111 annealing buffer were combined 
in a final volume of lOjii. The mixture was heated to 65°C for 2min and cooled slowly 
to room temperature. 
Polymerisation and elongation reaction: 
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I Opi annealed oligo/template, 1 p1 buffer B, 4pil deoxyribonucleotide mix, I p.! 1 OniM 
ATP, 2 units T4 DNA ligase and 2 units Kienow fragment were combined in 20pi final 
volume and incubated overnight at 15°C. 
5) Introduction into wild type E. coli: 
The double stranded products of the reaction were transformed into a repair-proficient 
(DUT, UNG) strain, NM522. This results in U-containing DNA being digested leaving 
the mutated T-containing clones. Mutant clones were identified by sequencing single 
stranded DNA from single transformants. This method reliably yielded at least 66% 
mutagenesis. 
Buffers. 
5X annealing buffer: 200mM Tris-HC1 pH7.5, 100mM M902, 250mM NaCl. 
Buffer B: 
0.2M Tris-HCI pH 7.5, 0.1M MgCl 2, O.IM DTT. 
Deoxyribonucleotide mix: 2mM each of dATP, dCTP, dGTP and dTTP. 
2.4.4.2 Site-directed mutagenesis by PCR. 
I) 0.3-6j.tg  each oligo and 50ng template DNA was assembled in a 100p.l reaction with 
lOp.! lox buffer (supplied with the polymerase) and lOp.l stock solution nucleotides. 
The lid of the tube was pierced and the contents overlaid with mineral oil. 
The reaction was heated to 91°C for 5min and cooled to room temperature. 
2.5 units of enzyme were added and the reaction put through 25 cycles as follows: 
I min 92°C, 
I min lowest Tm of oligos -5°C, 
2mm 72°C. 
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PCR reactions were stored at -20°C. 
2.4.5 Extraction of RNA from yeast. 
2.4.5.1 Small scale. 
lOmI yeast cells were taken from an exponential phase culture and harvested at 
4krpm in a benchtop centrifuge. 
The cell pellet was washed in TNE, spun down and either snap frozen at -70°C or 
resuspended in 300!iJ TNE. 
10mg acid washed glass beads and 300.tl phenol chloroform were added and 
vortexed for 2mm. 
After spinning to separate the phases, the aqueous phase was removed and extracted 
with phenol/chloroform (1:1) until the interface was clear. 
The RNA was precipitated with ethanol and resuspended in 50pJ dH 20. 
The yield was typically 1-2mg/ml. 
2.4.5.2 Large scale. 
A 200m1 culture was grown to 0D 600 0.3 to 0.7 before mixing with equal volumes of 
ice and harvesting at 4krpm at 4°C. 
The cell pellet was washed in 9m1 ice-cold TNE, resuspended in imi TNE and 
transferred to a 1 5m1 Corex tube. 
30mg acid washed glass beads were added and the tube vortexed for 1mm. 
3m! TNE, 200.i 20% (w/v) SDS and 4m1 phenol were added RAPIDLY before 
vortexing again for 1-5mm. 
5) The aqueous phase was repeatedly extracted with phenol until the interface was clear. 
FIE 
The aqueous phase was extracted once with chloroform and the RNA precipitated by 
adding 0.1 volumes of 3M sodium acetate pH5.3 and 2 volumes ethanol. 
After spinning at lokrpm at 4°C for 30mm, the pellet was washed with 70% ethanol, 
air dried and dissolved in 200pl ddH20. 
This yields 0.1.1.0mg RNA/200m1 cells at 0D 600 0.4. 
RNA was stored at -20°C. 
Buffers. 
TNE: 50mMTris-HC1 pH7.5, 5mM EDTA, 100mM NaCl. 
2.4.6 Denaturing agarose gel electrophoresis of RNA. 
2.1g agarose was added to 15m1 lox MOPS buffer and 130.5m1 dH 20, and boiled to 
dissolve the agarose. 
After cooling to below 65°C, 7.65m1 formaldehyde (37%) and 7.5pi Smg/ml 
ethidium bromide were added and the gel poured. 
30j.tg total yeast RNA was added to an equal volume of Formamide Sample Buffer 
(FSB) and heated to 65°C for 5mm. 
Samples were dry-loaded and run into the gel before covering the gel with running 
buffer. Empty wells at each side were loaded with agarose gel loading buffer to follow 
the course of the electrophoresis. The buffer was circulated by a peristaltic pump during 
electrophoresis. 




lox MOPS buffer: 41.86g MOPS, 6.81g sodium acetate, 3.72g EDTA. pH was adjusted 
to 7.0 with 5M NaOH. 
FSB: lOOpi lox MOPS buffer, 200p.i formamide, 120g1 formaldehyde (37%). 
Agarose gel loading buffer: 0.25% bromophenol blue, 0.25% xylene cyanol, 20% 
glycerol, 10mM EDTA. 
2.4.7 Capillary blotting of DNA and RNA. 
DNA or RNA from agarose gels was blotted onto Hybond-N membrane (Amersham) by 
drawing IX SSC through the gel as described by Sambrook et al (1989). Prior to 
assembling the blot, the gels were treated as follows: 
RNA gels were washed twice in IX SSC for 20 min each wash. 
DNA gels were washed twice in denaturation buffer (0.5M NaOH, 1 .5M NaCI) for 20 
min each wash, then washed twice in neutralising solution (0.5M Tris HCl pH7.4, 1.5M 
NaCl) again for 20 min each wash. 
After transfer, the nucleic acids were crosslinked to the membrane by exposure to UV 
light in a UV Stratalinker 1800 (Stratagene) on the auto-crosslink setting. 
2.4.8. Labelling restriction fragments by random priming. 
Modified from Feinberg and Vogelstein (1984). 
2-10tg plasmid DNA was digested to completion and electrophoresed through an 
agarose gel. 
The DNA fragment required was purified from the gel using Qiaex resin following 
the suppliers instructions. 
5) 50-10ng purified fragment was made up to 35pi with ddH20 and denatured by 
heating to 95°C for 5min before cooling on ice. lOj.il  OLB, 2.tl BSA at lOmg/ml, 
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I OpCi [a32-P]dCTP and 2 units Kienow were added and the reaction incubated at room 
temperature overnight. 
Buffers. 
Solution 0: 1.25M Tris-HC1 pH8.0, 0.125M MgCl2- 
Solution A: imi solution 0, 18jil J-mercaptoethanol, 5jL1 0.1mM each dATP, dGTP and 
dTTP. 
Solution C: Random hexadeoxyribonucleotides (Pharmacia) at 90 OD units/ml in TE. 
OLB was made by mixing solutions A:B:C in the ration 2:5:3, and was stored at 
-20°C. 
2.4.9 Hybridisation of Southern and Northern blots with random primed probes. 
I) Blots were prehybridised at 65°C in bottles in a Hybaid hybridisation oven for 2h in 
lOmi hybridisation buffer (Church and Gilbert, 1984). 
The probe was added following denaturation by heating to 95°C for 5mm. 
Hybridisation was carried out at 65°C for 16-24h. 
The membrane was washed X3 at 65°C with Church and Gilbert wash buffer. 
The membrane was wrapped in Saran Wrap and subjected to autoradiography at 
-70°C. 
Buffers. 
Hybridisation buffer: 7% SDS, 0.5M NaPO 4 pH7.2, 1mM EDTA. 
Wash buffer: 5% SDS, 40mM NaPO 4 pH7.2, 1mM EDTA. 
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2.4.10 Hybridisation of blots with radiolabelled oligos. 
2.4.10.1 Labelling an oligo probe. 
20pmol oligo was incubated with 20J.tCi 7-[ 32P] ATP, 100mM Tris-HCI pH8.0, 5mM 
DTT, 10mM M902 and 5 units T4 polynucleotide kinase for 45 min at 37°C. The 
enzyme was inactivated at 65°C for 10mm. 
2.4.10.2. Hybridising the blot. 
Blots were pre-hybridised, hybridised, and washed as above. If there were any 
mismatches between the probe and the substrate, the hybridisation temperature was 
lowered by 5°C per mismatch. 
2.4.11 In Vitro transcription. 
Davanloo et al (1984). 
0.2p.g linearised plasmid DNA, 1.tl lOX reaction buffer, ipi nucleotide mix, 3090 [ 
ct32P]UTP (800Ci/mmol) and 10 units RNasin (Promega) were combined in a final 
volume of 9.5il. 
0.5tl T7 RNA polymerase was added and the reaction incubated at 37°C for 12mm. 
The reaction was stopped on ice and used directly in splicing reactions or frozen at 
-20°C for up to three days. 
Buffers. 
lOX reaction buffer: 400mM Tris-HC1 pH8.0, 100mM MgCl 2, 100mM DTT, 100mM 
NaCl. 
Nucleotide mix: 5mM each ATP, CTP, GTP, 0.25mM UTP (Pharmacia T7 grade). 
2.4.12 Denaturing polyacrylamide gel electrophoresis of DNA and RNA. 
DNA and RNA were electrophoresed through 6% (w/v) acrylamide 7M urea gels at 
33W. Gels for running DNA samples (sequencing) contained 1X TB buffer, and gels 
for running RNA samples (splicing) contained 1X TBE buffer (section 2.1.9). 
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2.5 PROTEIN AND IMMUNOLOGICAL METHODS. 
2.5.1 General. 
2.5.1.1 Ouantitation of proteins. 
Protein concentration was determined using the Bradford Assay (Bradford, 1976). The 
dye concentrate (Bio-Rad) was used according to the suppliers instructions. BSA was 
used to generate standard curves. 
2.5.1.2 Induction of protein by galactose. 
Cultures of the strain to be induced were grown in YMGlyLacCas plus appropriate 
amino acids to 0D600 0.5, then induced by the addition of sterile 40% galactose to 2% 
final volume for a further 5h. 
2.5.2 Extraction and SDS-polyacrylamide gel electrophoresis of yeast proteins. 
2.5.2.1 Extraction of yeast total protein. 
lOOmI cultures were grown to 0D600 0.7 before harvesting in a benchtop centrifuge. 
The cell pellet was washed once in TBS before being resuspended in 0.4ml 
TBS/NP40 and transferred to a microcentrifuge tube. 
The cell suspension was sonicated on ice 3 times for 30sec each at 30sec intervals. 
Cell debris was removed by spinning for 30sec. 
The supernatant was transferred to a fresh tube and spun for 15min at 4°C to remove 
further debris. 
The supernatant was transferred to a fresh tube and frozen rapidly in solid CO2 before 
being stored at -70°C. 
Buffers. 
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TBS: 50mM Tris-HC1 pH8.0, 150mM NaCl. 
TBSINP40: TBS with NP40 added to 1% (v/v). 
2.5.2.2 SDS PAGE of proteins. 
Proteins were separated by discontinuous SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) as described by Laemmli (1970). 7.5% resolving gels were cast between 
l6xl6cm glass plates with 1.5mm spacers, leaving room for a stacking gel and left to 
polymerise for lh. The 6% stacking gel was then cast on top and the comb inserted. 
Protein samples were prepared by adding and equal volume of 2X sample buffer, 
heating to 95°C for 15min and centrifuged before loading. Gels were run at 20-3OmA in 
SDS-PAGE running buffer. 
Buffers. 
Resolving gel buffer: 1.5mM Tris-HC1 pH8.8, 0.4% (w/v) SDS. 
Stacking gel buffer: 500mM Tris-HC1 pH6.8, 0.4% (w/v) SDS. 
2.5.3 Silver staining of protein gels. 
Based on the method of Ansorge (1985). 
Protein gels were incubated in a series of buffers at room temperature as follows. 
50% methanol, 12% trichloroacetic acid, 2% CuC12 for 20mm. 
Solution A for 10 mm (all incubations from this point are for 10mm). 





0.1% AgNO3 (made up immediately prior to use). 
The gel was then washed three times with dH20 for 20sec each. 
The gel was washed for I min with 10% K2CO3- 
The stain was developed with up to 3 batches of developer until bands were 
visualised. 
II) The gel was then rinsed in solution A for Imin before drying. 
Buffers. 
Solution A: 10% ethanol, 5% acetic acid. 
Developer: 2% K2CO3,  0.01% formaldehyde. 
2.5.4 Western Transfer. 
After SDS-PAGE, the protein was electrophoretically transferred to Immobilon P in a 
Bio-Rad Trans-blot cell with two cooling coils. 
Following transfer the membrane was stained with Ponceau S (Sigma) and rinsed 
with water to remove excess stain. 
After the position of the Ponceau-stained markers were marked on, the membrane 
was incubated in blocking solution for lh. 
The blocking solution was discarded and the membrane incubated with the primary 
antibody (either 300ii affinity purified or 25pi crude) in I Sml blocking solution for lh 
at room temperature or overnight at 4°C. 
The membrane was washed X4 in TBS, 5min each wash, at room temperature. 
The membrane was then incubated with the secondary antibody (alkaline 
phosphatase-conjugated goat anti-rabbit, Promega) at the recommended dilution 
(1:7500) in TBS. 
as 5). 
5m1 development solution containing 0.33mg/mi NBT and 0.165mg/mi BCIP was 
used to detect bands on the washed membrane. 
After development, the blot was washed in water, dried and stored in the dark to 
minimise fading. 
Buffers. 
Transfer buffer: 20mM Tris base, 150mM glycine. 
Blocking solution: 5% (w/v) BSA in TBS. 
Development solution: 100mM Tris-HCI pH 9.5, 100mM NaCl, 50 MM MgCl2- 
2.5.5 Affinity purification of antibodies. 
A strip of membrane carrying the antigen of interest was incubated with blocking 
solution for 2-4h at room temperature. 
The membrane was incubated with lOmi blocking solution plus 1:100 - 1:300 
dilution of polycional antiserum for 2-3h at room temperature of 4°C overnight. 
The membrane was washed five times with 1X TBSIO.l% NP40. 
The antibodies were eluted by incubating in 2ml elution solution for 5mm. 
The eluate was removed and immediately added to 0.5m1 1M Tris pH 7.5. 
Steps 4) and 5) were repeated. 
The eluates were pooled and dialysed against 3 changes of 11 1X TBS for 16-20h at 4 
OC 
The affinity-purified antibodies were stored at 4°C after the addition of 0.1% sodium 
azide. 
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2.5.6 In vitro splicing. 
2.5.6.1 Preparation of yeast splicing extracts. 
Modified from Lin eta!, (1985). 
4Xll cultures were inoculated with a fresh stationary culture and grown overnight to 
0D600 0.6-0.8. 
The cells were spun down at room temperature and washed in 50mM potassium 
phosphate pH 7.5. 
The cells were resuspended in lyticase buffer and transferred to a conical flask. 5000-
8000 units of lyticase (Sigma) dissolved in lyticase buffer was added and the cells 
incubated with GENTLE agitation for 45min-1h. 
Cells were checked for spheroplast formation. (A few microlitres of spheroplasted 
cells were incubated in either water or 1.2M sorbitol for a few minutes. On examination 
under a microscope, whole cells should be seen in sorbitol, and lysed cells seen in 
water.) 
The spheroplasts were spun down at 3.5krpm and washed twice in 1.2M sorbitol, 
resuspending gently to keep the spheroplasts intact. 
The spheroplasts were washed once in ice cold SB-3 and placed on ice. Every step 
from now on was carried out at 4°C. 
The cell pellet was weighed and resuspended in lml buffer A for each g of cells. This 
suspension was transferred to a chilled Dounce homogeniser and homogenised with 12-
14 strokes of the pestle. 
The homogenate was transferred to a beaker on a magnetic stirrer at 4°C. The 
volume was measured and 1/9th  volume 2M KC1 dropwise while stirring. The extract 
was stirred for a further 30mm. 
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The extract was transferred to a chilled polycarbonate centrifuge tube and the cell 
debris removed by pelleting at 17krpm for 30mm. 
The supernatant was transferred to a chilled 50Ti polycarbonate bottle avoiding as 
much of the top lipid layer as possible, and also avoiding the pellet. (An optional second 
clearing spin can be performed at this stage.) 
The extract was then spun at 37krpm for I h at 4°C in a pre-cooled 50Ti rotor. 
Again avoiding any pellet or lipid, the supernatant was transferred to dialysis tubing 
and dialysed for 3h against buffer D with two or three changes of buffer. 
The extract was aliquoted into microcentrifuge tubes and frozen rapidly in solid CO 2 
before storage at -70°C. 
Buffers. 
Lyticase buffer: 1.2M sorbitol, 50mM potassium phosphate pH7.5, 30mM DTT* 
SB-3: 50mM Tris-HC1 pH7.5, 10mM MgC1 2, 1.2M sorbitol, 3mM DTT*. 
Buffer A: 10mM HEPES-KOH pH 7.5, 1.5mM Mg C1 2 , 10mM KC1, 0.5mM DTT* 
Buffer D: 20mM HEPES-KOH pH 7.5, 0.2mM EDTA pH8.0, 50mM KC1, 20% (v/v) 
glycerol, 0.5mM DTT* 
*DTT was added immediately prior to use. 
2.5.6.2 In vitro splicing. 
1) Reaction mix for 10 reactions was assembled: lOpi 30% (wlv) PEG 8000 (Sigma), 8p. 
I IgG buffer, 6jt1 1M potassium phosphate pH 7.5, 2.5il 100mM M902, lOj.tl 20mM 
ATP and 1000cps substrate RNA (prepared by in vitro transcription, section 2.4.13) in 




The reaction mix was aliquoted into 5pi volumes and 5p1 splicing extract added to 
each aliquot. This was incubated at 25°C for 30min before stopping the reaction on ice. 
2tl proteinase K solution was added to digest the protein and incubated at 37°C for 
30mm. 
100tl splicing cocktail was added and the sample extracted twice with 
phenol/chloroform and precipitated with ethanol after the addition of 2ig tRNA as a 
carrier. 
The pellet was dried under vacuum and resuspended in 3p1 Sanger dye before heating 
to 75°C for 2mm. 
The heated samples were briefly spun down then electrophoresed through a 6% (w/v) 
denaturing acrylamide gel and detected by autoradiography. 
Buffers. 
IgG buffer: 0.5M KPO 4 pH7.5, 33mM citrate pH 3.0, 16.67% glycerol. 
Proteinase K solution: 50mM EDTA, 1% (w/v) SDS, 1mg/mi proteinase K. 
Splicing cocktail: 50mM sodium acetate pH5.3, iniM EDTA, 0.1% (w/v) SDS, 
25pg/ml E.coli tRNA. (E.coli tRNA was dissolved in dH20 and extracted with 
phenol/chloroform several times before being precipitated with ethanol and re-dissolved 
in dH2O.) 
Sanger dye: 50% (v/v) formamide, 20mM EDTA, 0.3% xylene cyanol FF, 0.3% 
bromophenol blue. 
2.5.7 Native gel electrophoresis of splicing complexes. 
Adapted from Pikielny eta! (1986). 
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2.5.7.1 Pouring the gel. 
1 50x 1 50x 1.5mm composite agarose/acrylamide gels were run in A'FTO electrophoresis 
tanks. 
3-4cm blocking acrylamide (imI 30% (w/v) acrylamide, 100tl 0.5M EDTA, 250g1 
lOX TB, 3.65m1 dH20, 50pJ 10% APS, 20pi TEMED) was poured into the gel plates 
and placed at 37°C to set. (This prevents the composite gel from sliding out of the plates 
during electrophoresis.) 
2.5m1 1OXTB, lml 0.5M EDTA and 5m1 30% acrylamide: bisacrylamide 30:0.8was 
combined and placed at 65°C. 
0.25g agarose was dissolved by boiling in 40m1 dH 20 and cooled to around 37°C. 
At 37°C, the agarose and acrylamide solutions were combined and made up to 50m1 
with dH20 at 37°C. 0.4m1 10% APS and 50j.il TEMED were added, the solution mixed 
by inversion and poured into the plates. A comb was quickly inserted and the gel left at 
37°C for around 30mm. 
The gel was chilled to 4°C overnight before use. 
2.5.7.2 Running the gel. 
The gel was pre-electrophoresed at 4°C for 30min in RNP running buffer at 80V. 
Splicing reactions were set up as in section 2.5.6.2 as far as step 2). 
5p1 aliquots were removed from the splicing reaction and added to 5.tl Q buffer on 
ice. 
2.5pJ 5X RNP loading buffer was added to each sample, loaded on the gel and run at 
4°C for 8-1Oh at 80V or overnight at 30V. 
Buffers. 
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RNP running buffer: 0.5X TB, 10mM EDTA. 
Q buffer: 1.6M KC1, 8mM magnesium acetate, 80mIvI EDTA, 64m1v1 Tris-HC1 pH7.5, 
2.6mg/mi yeast total RNA (prepared as in section 2.4.6 then extracted with 
phenol/chloroform a further 5-6 times and re-precipitated with ethanol). 
5X RNP loading buffer: 5X TB, 50mM EDTA, 50% (v/v) glycerol, 0.25% (w/v) each 
bromophenol blue and xylene cyanol FF. 
2.5.8 Preparation of APRP2 AATP spliceosomes. 
2.5.8.1 Heat inactivation of DJy85 (pry2-1) splicing extract. 
50p1 DJy85 splicing extract was added to 1O.tl 30% PEG, 8tl IgG buffer, 6jil IM 
potassium phosphate pH7.5 and 2.5jil 100mM MgCl2- 
This was incubated at 37°C for lh. 
For splicing, substrate RNA and ATP was added and the reaction carried out as 
described in section 2.5.6.2. For APRP2 AATP spliceosomes, the following procedure 
was carried out. 
2.5.8.2 Spliceosome assembly. 
1 OOpi reactions were set up containing heat inactivated DJy85 as above, 1.5mM ATP 
and substrate RNA to 500cps. The reaction mix was incubated at 25°C for 30mm. (5 
lOOpi reactions provided enough spliceosomes for 10-12 splicing reactions.) 
1 .5mM glucose (final volume) was added to the reaction mix and incubated at 25°C 
for a further 5mm. This depleted the ATP in the extract by making use of the 
endogenous hexakinase activity. 
The spliceosomes were isolated on a Sephadex G25 column (NAP-5, Pharmacia). 
The column was equilibrated with splicing reaction mix (section 2.5.6.2) without ATP, 
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and the reaction mix made up to imi with splicing reaction mix prior to loading on to 
the column. 
4) The column was washed with 1-2m1 of splicing reaction mix and 120p1 fractions 
collected, numbered 1-10. The 4 or 5 hottest samples (usually fractions 3-7) containing 
the spliceosomes were pooled, aliquoted and either used immediately or stored at -70°C 
for up to 24h. 
2.5.9 Immunoprecipitation. 
Lossky et al (1987) 
PAS beads (Sigma) were swollen in imi NTN for 20min and washed 5 times with 
NTN. 7.5mg dry mass (50tl swollen beads) were used per reaction. 
The antibody was added to the beads at sufficient titre to give maximal precipitation 
of antigen, and incubated in 300pi NTN with mixing for lh. In this case, 90jtl anti-54 
was used per reaction. 
200pi freshly made blocking buffer was added and incubated with mixing for a 
further 45 mm. 
The beads were washed 5 times with NTN and placed on ice until the splicing 
reaction was ready. 
A 10tl splicing reaction was set up and taken through to step 2 (section 2.5.6.2). 
lOpi ice cold Q buffer was added and NTN was added to give a final volume of 300j.il. 
This was added to the antibody-bound PAS beads and incubated at 4°C for 2h with 
mixing. 
The beads were washed several timed with washes of imi NTN and monitored until 
the signal from the negative control is minimal. The beads were then washed once in 
NT 
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To analyse RNA, 501Ji proteinase K solution was added and incubated at 37°C for 
30min with mixing. 
50p1 dH20 was added and the sample extracted 3 times with phenol/chloroform. 
The RNA was precipitated with ethanol adding lp.l E.coli tRNA at 20mg/mi as a 
carrier. 
The samples were electrophoresed through a 6% (w/v) denaturing acrylamide gel 
before exposure to autoradiography at -70°C. 
Buffers. 
Blocking buffer: 100pg/ml each of BSA, glycogen and E.coli tRNA, used fresh. 
Q buffer: (check recipe for RNP gels) 
NT: 150mM NaCl, 50mM Tris-HC1 pH7.5. 
NTN: as NT but with 0.1% (v/v) NP40. 
Proteinase K solution: 50m1V1 Tris-Hcl pH7.5, 300mM NaCl, 5mM EDTA, 1.5% (w/v) 
SDS, 2mg/mi proteinase K (stored at -20°C). 
2.5.10 Purification of polyhistidine-tagged Prp2 protein from yeast. 
2.5.10.1 Preparation of splicing extracts for purification of Prp2 protein. 
S150 cells carrying the inducible allele of PRP2 to be purified on a plasmid were 
grown in YMGlyLacCas and induced as described in section 2.5.1.2. 
The splicing extract described in section 2.5.6.2 was carried out except that no DTT 
was added to buffer a or SB-3, and the final dialysis step into buffer D was omitted. 
The extract was snap frozen and stored at -70°C before purification. 
MCI 
2.5.10.2 General guidelines. 
Columns were run at 4°C. All buffers were cooled to 4°C before use. A peristaltic 
pump was used to control the flow rate through the columns. The volume referred to in 
the following sections is the volume of packed resin in the column. A 1.77cm 2 (5cm 
long) column was used for the nickel-chelating column, and a 0.2cm 2 (5cm long) 
column was used for the polyuridylic acid agarose column. 
2.5.10.3 Nickel chelating column. 
Hoffman and Roeder (1991). 
Packed Ni-NTA resin was washed with 40m1 pre-wash at a flow rate of 20m1/h for 
2h. 
Splicing extract was added to an equal volume of 2X sample buffer and I mlvi 
imidazole and circulated through the column for 3-4h at a flow rate of 15m1/h. 
The column was washed with 30ml 20mM imidazole pH7.9 in BC 100 at 15ml/h. 
The column was washed with 20m1 50mM imidazole as in step 3. 
Protein was eluted from the column in 5ml 150mM imidazole followed by 5m1 
200mM imidazole at a flow rate of Smllh. 
Buffers. 
Pre-wash: 20mM Tris-HC1 pH7.9, 0.5M NaCI. 
2X sample buffer: 20mM Tris-HC1 pH7.9, 1M NaCl, 20% glycerol. 
BC100: 200mM Tris-HC1 pH7.9, 100mM KC1, 20% glycerol. 
IM imidazole was made up in dH 20 and pH adjusted to pH7.9 with HC1 before dilution 
with BC 100 to make 20, 50, 150 and 200mM solutions. 
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2.5.10.4 Polyuridylic acid agarose column. 
Adapted from Kim et al (1992). 
300mg polyuridylic acid (poly(U)) agarose was swollen in 3m1 BP buffer for 30mm 
with mixing. 
Swollen poly(U) was packed in to form a Imi column. 
The column was washed with 20ml BP containing 50mM KCI at a flow rate of 
l5mlIh. 
Peak fractions (as identified by Western blotting) from the Ni-NTA column, which 
had been pooled and dialysed against buffer D (section 2.5.6.1) for 2h at 4°C with a 
change of buffer after lh, were circulated over the column at a flow rate of 15mlIh for 
The column was washed with 20m1 BP plus 100mM KC1 followed by lOml BP 
containing 150mM KCI at a flow rate of 15ml/h. 
Prp2 protein was eluted with 5m1 BP/200mM KC1 and 5m1 BP/250mM KC1 at a flow 
rate of 5mllh. 0.5m1 fractions were collected and analysed by western blotting to identify 
peak samples and silver staining to assess purity. 
Buffers. 
BP: 20mM HEPES-KOH pH7.7, 0.5mM EDTA, 0.01% NP40, 10% glycerol, 5mM 
DTT* 
* DTT was added immediately before use. 
2.5.11 3-gaIactosidase assays. 
Miller, 1972. 
Cells were induced if necessary (section 2.5.1.2) and imi aliquots harvested in mid 
log phase. 
Cells were resuspended in 0.5m1 Z buffer. 
W. 
25p1 CHC13 was added and vortexed for 20sec. 
lOOp 1 ONPG was added and incubated at 23°C for 30min-5h. 
The reaction was stopped by the addition of 250j.tl IM Na2CO3. 
The cell debris was spun down and the supernatant assayed at 420nm. 
Buffers. 
Z buffer: 60mM Na2HPO4. 40mM NaH2PO4, 10mM KC1, 1mM MgSO4, 50mM 3-
mercaptoethanol, 0.025% (w/v) SDS. 
ONPG: 4mg/mi ONPG in 0. 1M potassium phosphate buffer. 
-gaiactosidase activity was calculated by the following formula. 
units of 3-galactosidase activity = 	OD420 . x 1000 
(t x 0D600 x V) 
Chapter three. 
Analysis of the zinc finger motif of PRP2. 
3.1 Introduction. 
Zinc finger motifs are known to be important in nucleic acid/protein binding. As 
splicing is a highly dynamic process involving a changing pattern of RNA/protein 
interactions, it is conceivable that RNA binding motifs including zinc fingers will be 
involved throughout the splicing process, and indeed, it has been shown that Prp9 
protein has zinc finger sequences required for splicing (Legrain and Choulika, 1990) and 
functions as part of a complex implicated in the addition of the U2 snRNA to the 
spliceosome (Legrain and Chapon, 1993). A similar motif is found in Pip ll protein 
(Chang et al, 1987). 
The function of the zinc finger domains of Prp9 and Prp6 proteins were investigated by 
Legrain and Choulika using site-directed mutagenesis and complementation of 
temperature-sensitive mutant strains. With Prp9, they found that by mutagenising the 
first histidine of the first zinc finger domain to leucine, or any cysteine or histidine in the 
second zinc finger domain to serine or leucine respectively, ability to complement the ts 
defect of the prp9 strain was lost. The cysteine and histidine residues of Prp6 protein 
were also mutagenised to serines and leucines respectively. In this case, plasmids 
carrying PRP6 with any one of the four positions mutated were able to complement a 
prp6 ts strain at the non-permissive temperature. 
The protein sequence of Prp2 contains a zinc finger-like motif towards the C-terminus. 
This motif is unusual in that instead of pairs of cysteine residues and histidine residues, 
it has three cysteine residues and one histidine. The alignment of the zinc finger-like 
sequence of Prp2 with other such sequences is shown in table 3.1. 








---F-----L-- H ---- 
(3-4) 
H 
Prp2 GTITRLGKMM C EF? C EPEFAXVLYTAAT H EQ C 
QGVLEECLTI 
Prp6 SVAKKIIENG C QE C PRSSDIWLENIRL H ESDV H YCKTLVATAI 
Prp9 SLRSEAKGIY C PF C SRWFKT S SVFES H LVGKI H KKNESXRRNF 
KLHGLDREYR C El 	C SNKVYNGRRT FER H FNEER H IYHLRCLGIE 
p 	ii IYKNHSGKLV C KL C NTMHMSWS SV ER H 
LGGKK H GLNVLRRGIS 
Table 3.1 Sequences from Prp2 protein (Chen and Lin, 1990), Prp6, Prp9 (Legrain and 
Choulika, 1990) and Prpll proteins (Chang et a!, 1988) are aligned with the consensus 
sequence of zinc finger motifs as derived from TFIIIA (Vincent, 1987). 
3.2 Results 
3.2.1 Mutagenesis of the second cysteine residue of the zinc finger motif results in a 
non-functional Prp2 protein. 
To investigate the zinc finger motif in the Prp2 protein, in vitro mutagenesis was used to 
make changes in PRP2 resulting in substitutions of the cysteine and histidine residues in 
the zinc finger motif. 
The first mutation made to investigate the function of the zinc finger motif was a change 
of the second cysteine residue to tyrosine (Figure 3.1). The mutation, made by Erica 
Whittaker, was introduced by site-directed mutagenesis in M13 as described in section 
2.4.4, using M13T3B as a template and oligo 026A. The resultant mutant construct was 
called M13P2C2. 
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Figure 3.1 Wild-type sequence of the zinc finger motif of Prp2 protein showing 
position of the P2C2 mutation. 
GTITRLGKMM 	C EFP C 	EPEFAKVLYTAAT 	H EQ C 	QGVLEECLTI 
Y 
Figure 3.1. The second cysteine residue of the putative zinc finger was changed to tyrosine 
by site-directed mutagenesis. 
3.2.2 Construction of a galactose-controllable mutant allele. 
In order to investigate the behaviour of the P2C2 mutant, a galactose-inducible construct 
was used. pBMPRP2 contains the GAL] promoter. This allows control over the 
expression of PRP2 by growing on glucose, which represses expression, or growing on 
galactose, where expression is induced, allowing the allele to be overexpressed. 
Figure 3.2. Sequence of pTZP2C2 showing the G to A mutation. 
A G C T 
Figure 3.2 A 2.4kb HindIII-XbaI fragment was subcloned from pBMP2C2 recombinants 
into pTZ19R. Template DNA from pTZP2C2 was sequenced to confirm the presence of the 
G to A mutation. 
The PvuH-XbaI fragment of pBMPRP2 was removed and replaced with the Pvull-XbaI 
fragment of M13P2C2. This procedure carries some risk that resultant colonies contain 
the parent pBMPRP2 plasmid and not the recombinant pBMP2C2. These are 
indistinguishable by restriction digest. To confirm the identity of recombinant clones, a 
2.4kb Hind ffl-BamHI fragment from possible pBMP2C2 clones containing the zinc 
finger motif was subcloned into pTZ19R. Single stranded DNA was prepared from the 
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Figure 3.2 A 2.4kb HindIII-XbaI fragment was subcloned from pBMP2C2 recombinants 
into pTZI9R. Template DNA from pTZP2C2 was sequenced to confirm the presence of the 
G to A mutation. 
The PvuH-XbaI fragment of pBMPRP2 was removed and replaced with the Pvull-XbaI 
fragment of Ml 3P2C2. This procedure carries some risk that resultant colonies contain 
the parent pBMPRP2 plasmid and not the recombinant pBMP2C2. These are 
indistinguishable by restriction digest. To confirm the identity of recombinant clones, a 
2.4kb Jlindffl-BamHI fragment from possible pBMP2C2 clones containing the zinc 
finger motif was subcloned into pTZ19R. Single stranded DNA was prepared from the 
recombinant pTZ constructs and sequenced using oligo 027A as a primer. Figure 3.2 
shows the mutant sequence containing the G to A change. 
3.2.3 Complementation of a prp2- 1 temperature-sensitive strain. 
pBMPRP2, pBMP2C2 and pBMI25 were transformed into the yeast strain DJy36. 
DJy36 is a prp2-I strain which is temperature-sensitive, only growing at or below 30°C. 
The transformant colonies were purified and spotted onto selective glucose and 
galactose plates at 23°C and 36°C. 
Figure 3.3 shows that although the pBMPRP2 plasmid can complement DJy36 at 36°C 
on glucose and galactose, pBMP2C2 cannot complement the prp2-1 defect. 




Glu 	 Glu 	 Gal 
23°C 36°C 36°C 
Figure 3.3. Transformants of a prp2-1 is strain, DJy36, carrying pBMP2C2, pBMPRP2 
(positive control) or pBMI25 (negative control) were spotted onto galactose plates and 
grown at the pemissive (23°C) or non-permissive (36°C) temperature. The cells 
transformed with pBMP2C2 fail to grow at the non-permissive temperature, so the P2C2 
mutant fails to complement the prp2-I is defect. 
Transformants on plates incubated at 30°C and below grow, indicating that pBMP2C2 
plasmid does not confer cold sensitivity on the cells. 
To check that the absence of complementation by pBMP2C2 was not due to lack of 
expression of the protein, western analysis of cultures grown under inducing and non- 
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inducing conditions was carried out. Western analysis (figure 3.4) shows that the 
mutant protein is overexpressed in the presence of galactose, so lack of 
complementation is not due to absence of the protein. 




Figure 3.4. Cultures of DJy36 transformed with pBMP2C2 were grown in selective glucose 
(Glu) or galactose (Gal) medium. Equal amounts of extract as determined by Bradford 
assay were separated by SDS-PAGE and transferred to Immobilon-P by electroblotting. 
The membrane was probed with anti- 140 antiserum. 
3.2.4. Construction of pSA1, pSA2 and pSA3 as cloning vehicles. 
To facilitate the construction of further recombinant mutant constructs and avoid 
possible confusion with the wild-type parent plasmids, a series of linker constructs were 
made. Using restriction sites unique to PRP2, fragments of PRP2 were removed from 
pBMPRP2 and replaced by short linkers (see table 3.2). 
Table 3.2. Regions of pBMPRP2 replaced by oligos to form linker constructs 
Plasmid Region of PRP2 removed Linker Oligos forming 
linkers 
pSAI 579bp PvuII-Saul fragment PvuH-SacI-Saul 449J/450J 
pSA2 582bp XbaI-PvuII fragment XbaI-SacI-PvuH 446K1447K 
pS A3 778bp HindIII-XbaI fragment Hindm-SacI-XbaI 484K148 5K 
For construction of subsequent mutant plasmids, the appropriate linker construct was 
cut with the two enzymes that cleave at either end of the linker. Following ligation with 
the mutant fragment, the recombinant DNA could be incubated with Sacl prior to 
transformation, thus reducing the background of non-recombinant constructs. 
Recombinants could easily be distinguished from the linker construct by restriction 
analysis. 
3.2.5 Further mutagenesis of the zinc finger motif. 
Further site-directed mutagenesis was carried out to characterise the zinc finger of the 
Prp2 protein. As shown in table 3.3, the C2, C3 and C4 residues were changed to 
serine, a more conservative change than tyrosine. The histidine residue was changed to 
leucine, also a conservative change. As there is a possibility that the C4 residue may 
compensate in the event of C3 being mutated, a double mutant was also constructed 
which contained both C3 and C4 residues mutated to serines. 
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Table 3.3 The zinc finger sequence of Prp2 protein and position of mutations. 
wild-type GTITRLGK4 C EFP C 
sequence  








P2C3  S 
P2C4  S 
P2dm  S S 
P2H L 
The C2S mutation was made by the Kunkel method of site-directed mutagenesis using a 
pTZPRP2 template. 
The remaining mutations were made by PCR using oligos which primed at the PvuII site 
carrying the mutations, and a wild-type oligo priming from the 3 BamHI site. The PCR 
products were cloned into pTZI9R by cutting with PvuII and BamHI, and sequenced to 
confirm the presence of the mutation. As Taq polymerase has a relatively low fidelity 
rate, the whole PCR fragment was sequenced to ensure that no mutations were present 
other than the desired change. 
Figure 3.5. Complementation of a prp2-1 ts strain by zinc finger mutants. 
3.-' 
3.5b 
Figure 3.5. DJy36 (prp2-1) was transformed with pBMP2-series plasmids carrying 
mutations as detailed in table 3.3. Colonies from purified transformants were suspended in 
sterile water and spotted onto selective plates. A transformant carrying pBMPRP2 was used 
as the positive control (+), which grows at all temperatures, and one of pBM125 was used 
as the negative control (-), which grows at or below 30°C. 3.5a shows that all the 
tranformants grow on glucose at the permissive temperature, 23°C. Figure 3.5b shows that 
at the non-permissive temperature, 36°C, background expression from the GAL] promoter 
is sufficient for all the point mutants to rescue the ts defect of DJy36 on glucose. Cells 
transformed with the negative control fail to grow at this temperature. 
In the case of the double mutant, PCR was carried out using a template containing the 
C4-S mutation, the C3-S mutation being introduced by oligol64H during the second 
round of PCR. 
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After sequencing confirmed the presence of the desired mutations, PvuHISauI mutant 
fragments were ligated into the pSAI linker construct. 
The new mutant constructs were transformed into the prp2-I strain DJy36 and tested for 
complementation on glucose and galactose. Figure 3.5 shows that all the mutants can 
complement the prp2-1 ts defect even on glucose medium at the non-permissive 
temperature, 36°C. 
3.2.6 Insertion of the JB1 oligo adds four amino acids to the loop of the zinc linger. 
It was decided to further investigate the role of the putative zinc finger in the Prp2 
protein by inserting an oligo into the PvuII site in the zinc finger loop. 
The JB I oligo is self-complementary so was annealed and ligated into the PvuII-cut 
pBMPRP2. This inserts four additional amino acids into the loop of the zinc finger 
(figure 3.6). The insertion carries a diagnostic ClaI site which was used to screen 
recombinant plasmids for insertions. Cutting the recombinant pBMPRP21n5 with ClaI 
confirmed that the insertion was present. 
Figure 3.6 ClaI insert oligo and surrounding sequence of PRP2. 
DNA sequence 	TAT ACA GCTAAT CGA 77A GCT GCT ACG 
Protein sequence 	Y T A N R L A A T 
Figure 3.6. Sequence of PRP2 with the PvuII site highlighted in bold type. The oligo 
insertion is indicated in italics. Amino acid sequence is shown below each codon with 
inserted residues in italics. The diagnostic C/al site in the oligo is underlined. 
To confirm the insertion of one oligo repeat, a 2.4kb Hind ffllBarnHI fragment was 
subcloned into pTZ19R and sequenced using oligo 1970. This verified the presence of 
one copy of oligo. 
3.2.7 pBMPRP2ins is unable to fully complement a temperature-sensitive prp2-1 
strain. 
pBMPRP2ins was transformed into the temperature-sensitive prp2-1 strain DJy36. 
When expression of the mutant gene was induced by growth on galactose plates, this 
construct complemented the temperature-sensitive defect of prp2-I up to 34°C but not 
above (figure 3.7). Under repressing conditions on glucose plates, no complementation 
was seen, even although the wild-type construct is known to complement up to 36°C on 
glucose. This complementation by the wild-type allele is due to incomplete repression 
of the GAL] promoter by glucose. 





Figure 3.7. Transformants of the temperature-sensitive strain, DJy36, were suspended in 
sterile water and spotted onto selective galactose plates as before. Plates incubated at 34°C 
showed complementation by pBMP2ins, but plated incubated at 36°C did not. 
3.2.8 Construction of SAyl disrupted diploid. 
As the complementation assays seemed to give contradictory results , it was decided to 
assay the mutants another way, by replacing the genomic copy of PRP2 with the mutant 
alleles. As PRP2 is an essential gene, gene disruption and replacement is carried out in 
Me 
a diploid strain in which only one of the PRP2 alleles is disrupted. The phenotype of 
the replaced gene can then be assayed after sporulation and tetrad analysis. 





XIa1 PvuII  Squl 
EFyI 
0.8kb 	1.1kb 	2.3kb 
EFyI has one chromosomal locus disrupted by HIS3 inserted at the Hindu! site. PRP2 
sequence contains the zinc finger motif (on either side of the PvuII site). 
To remove the zinc finger sequence, this diploid was transformed with the 3kb BamHl 
fragment from the plasmid pEF2i, which carries PRP2 disrupted by URA3 and has the 
XbaI-SauI fragment removed. Transformants were selected on ura- plates and subsequently 





SAyI 	 PRP2 	URA3 	PRP2 J 
0.8kb 1.1kb 1.1kb 
A previously constructed diploid carried a disruption that still contained the zinc finger 
region of the PRP2 ORF. To facilitate construction of a strain to assay the zinc finger 
mutants, a diploid strain had to be constructed in which the disrupted locus did not 
contain the zinc finger sequence. A strategy was developed to delete some of the PRP2 
sequence from the plasmid pEF2, which contains PRP2 disrupted by URA3. 
An Xbal/SauI fragment was cut out of pEF2, the ends of the plasmid filled in and ligated 
together. This plasmid was called pEF2A. The BamHI fragment from pEF2 
containing the disrupted PRP2 was gel purified and transformed into the diploid strain 
EFy 1 (a/a, ura3-521ura3-52, his3-Lt2001his3Al, ade2- 101 0CIADE2, lys2-801/LYS2, 
trp1-z1/rrp1 -289, LEU21leu2-3,112, PRP21prp2::HIS3) ( figure 3.8). EFyI carries a 
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prp2 allele disrupted by HIS3 and one wild-type PRP2 locus. The resulting 
transformants were tested for the desired phenotype: trp - , his- and Ura+. A Southern 
blot of genomic DNA probed with a fragment of PRP2 (figure 3.9, track 8) shows a 
band of the appropriate size. This strain was called SAy I. 
The genotype of SAy 1 is as follows: 
a/ct, ura3 -52/u ra3-52, his3-420017iis3Al, ade2- 1010C/ADE2, lys2 -80/IL YS2, rrp 1 -A 
1/trpl-289, LEU217eu2-3, 112, PRP21prp2:: URA3. 
3.2.9 Behaviour of zinc finger mutants on the genome. 
To place the zinc finger mutants on the genome, a 3kb BamHI fragment from each 
pBMP2-series mutant construct was gel-purified twice using the Qiaex system. The 
purified mutant fragments were transformed into SAy1 and grown on the appropriate 
selective medium containing 5-FOA to select against Ura transformants. 
Transformants were tested for the appropriate markers by growth on minimal medium 
lacking either uracil, histidine or tryptophan. Desired transformants were ura - , his- and 
trp - . A control transformation with no DNA was carried out. Southern analysis was 
carried out for each diploid strain before sporulation (figure 3.9). This showed that the 
disrupted prp2:: URA3 band seen in the untransformed parent strain had been replaced 
by one full length PRP2 band in each transformant. 
Figure 3.9 Southern blot of genomic DNA from SAyl following gene replacement 
with zinc finger mutations. 
1 	2 	3 	4 	5 	6 	7 	X 	9 
EcoPJ 	 BamHl 




Figure 3.9. Genomic DNA was isolated from diploid strains following gene replacement 
and digested with EcoRI and BarnHI. Following electrophoretic separation, the DNA was 
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transferred to Hyhond-N and the membrane probed with a 3kb Barn HI fragment of PRP2. 
The top band corresponds to the 3.2kb EcoRI-BarnHI fragment of PRP2 which includes the 
PRP2 promoter, the lower fragment corresponding to the disrupted prp2:: URA3. Tracks 
are as follows: I. P2C4; 2. P2H; 3. P2ins; 4. P2C2; 5. P2C2S; 6. P2dm; 7. P2C3; 8. SAyl; 
9. 3kb PRP2 fragment from pBMPRP2 plasmid. 
Tetrads were prepared from each transformed diploid by growing on sporulation 
medium for 3-4 days. Asci were scraped off the plate and resuspended in spore buffer 
as in section 2.3.6. Between 5 and 10 individual tetrads for each strain were dissected 
using a Singer MSM micromanipulator and the dissected spores grown on YPDA for 3-
4 days. Each tetrad yielded four viable spores. Auxotrophic markers were checked by 
growth on minimal medium to verify 2:2 segregation. All incubations up to this stage 
were carried out at 23°C. 
All haploid progeny derived for each tetrad were spotted onto plates and incubated at 18 
°C, 23°C, 30°C, 34°C and 36°C. The mutant alleles P2C2 and P21ns, which on 
plasmids had failed to complement the prp2-1 defect in DJy36, supported growth up to 
36°C when present as the chromosomal locus. Following this result, tetrads were 
dissected for another individual transformant of each mutant. Again, complementation 
was seen at the non-permissive temperature. Progeny resulting from the other mutants, 
P2C2S, P2C3, P2C4, P2dm and P2H, were tested and grew at all temperatures. 
3.3 Discussion 
The P2C2 and P2ins mutants showed some loss of function in the prp2-1 
complementation assay. Other substitutions of cysteine and histidine residues had no 
effect on the ability to complement the prp2-I ts defect of DJy36. It was considered 
that the full effect of mutations may not be observed in a prp2-I genetic background due 
to low level activity of the ts allele at the restrictive temperature, or possibly as a result 
of intragenic complementation. The ability of the mutant alleles to support growth as 
the sole copy of prp2 was therefore tested. 
The P2C2 and P2 ins mutants support growth when they are the sole sources of PRP2 in 
the cell (section 3.2.9). This seems contradictory to the initial result of not fully 
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complementing the ts defect of the prp2-1 strain. One possible explanation for this is 
that in a prp2-1 strain, the introduced mutant protein competes poorly with the prp2-1 
protein for interaction with spliceosornes. As the insertion mutant is slightly larger than 
the prp2-1 protein, the prp2-1 protein may compete more effectively for the 
spliceosomal binding site. In the case of the P2C2 mutant, the non-conservative 
substitution may result in a conformational change which interferes with the ability to 
enter the spliceosome to a greater extent than the more conservative substitutions. This 
may result in a greater defect in the protein which is manifested by the inability to 
complement the prp2-1 mutation. When these mutants are the sole source of Prp2 
protein in the cell, there is no competition so the cells are able to grow at all 
temperatures. Immunoprecipitation experiments with anti-Prp2 antibodies failed to 
show association of prp2-1 protein with the spliceosome (King and Beggs, 1990). 
However, this may be due the mutant protein being in a conformation not recognised by 
the antibodies. 
Another difference between the complementation of the ts defect and genornic 
expression of PRP2 is that in the former case the mutant proteins are being highly 
produced. It is conceivable that the mutant proteins become dominant negative at 
temperatures above 30°C when overproduced despite being functional at normal levels 
of expression and at lower temperatures. One possibility might be that the transient 
interaction of Prp2 with the spliceosome is critical such that an interacting factor must 
be made available for a different interaction subsequent to Prp2 function. If the mutant 
protein has an altered affinity for this factor, overproduction combined with higher 
temperatures could be detrimental. 
An interesting experiment would be to construct a series of mutants with multiple 
inserts of the JB I oligo and screen for an exaggerated phenotype. 
In the case of the other mutants, i.e. P2C3, P2C4, P2H, P2C2S and P2dm, it was 
theoretically possible that the function of these proteins was affected to some minor 
degree but this was not manifested as a ts defect in the presence of prp2-1 protein. 
However, as these proteins appear fully functional as the sole source of Prp2 in the cell, 
complementation by heterodimerisation or intragenic complementation is ruled out. 
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These "silent" mutations may prove synthetic lethal in combination with mutant co-
factors, as yet unidentified, or even with intragenic mutations. 
Zinc fingers rarely work in isolation, as there are usually several consensus sequences 
within the one protein eg. TFIIIA which has 9, so it is a possibility that another domain 
in Prp2 is capable of compensating for some loss of function of the zinc finger. The 
Prp2 protein is known to bind RNA although the exact RNA binding site is unknown 
(Plumpton eta!, 1994; Teigelkamp eta!, 1994). 
When the RNA binding site of Prp2 is elucidated, it would be interesting to combine 
mutations in the RNA binding site with mutations in the zinc finger. In the event of 
single mutations in the RNA binding site having no detectable phenotype, it is possible 
that combined RNA-binding/zinc finger mutants would exhibit a gross detectable 
defect, or that a subtle phenotype may be exacerbated by combining mutations. 
Many examples of redundant structures in the spliceosome are coming to light. In the 
case of snRNAs, highly conserved sequences most notably in the U2 and U6 snRNAs 
can be mutated with no effect on the cell growth. The U2/1J6 helix II involves base 
pairing between the 5' end of the U2 snRNA and the 3' terminal domain of the U6 
snRNA. This structure would appear to be important for the splicing process in 
mammalian cells (Datta and Weiner, 1991, Wu and Manley, 1991). In yeast, mutations 
in the U6 snRNA that have little or no effect on cell growth (Fabrizio et a!, 1989, 
Madhani eta!, 1990) were later found to disrupt this helix (Madhani and Guthrie, 1992, 
Hausner et al, 1990). More recently, the U21U6 helix HI has been described (Yan and 
Ares, 1996). Single mutations in U2 which disrupt this helix have no effect on cell 
growth, but double and triple mutants were found to be lethal. Other highly conserved 
sequence elements in yeast which appear to be dispensable include the stem-loop I of 
the U I snRNA (Liao et a!, 1990) and the base pairing between U4 and U6 (Fabrizio and 
Abelson, 1990). 
In the case of spliceosomal proteins, mutations in different domains of Ussi protein, a 
U6-specific splicing factor, inactivate the function of the protein when in combination, 
but not individually (M. Cooper, unpublished results). 
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It remains a possibility that the zinc finger motif in Prp2 is similarly redundant and the 
function has been taken over by another splicing factor. In this scenario, the P2C2 and 
P2ins insertion mutants may cause disruption to the conformation of the Prp2 protein, 
resulting in the observed phenotype. The other more conservative mutations may not be 
so disruptive to the protein's conformation and are therefore silent. 
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Chapter four. 
Deletion analysis of dominant negative alleles of PRP2. 
4.1 Introduction 
As the Prp2 protein has a transient interaction with the spliceosome, conditional 
dominant negative mutations were generated which froze this interaction, leaving Prp2 
stably associated with spliceosomes which are unable to undergo step one. When these 
dominant negative mutant proteins are introduced they compete with wild-type Prp2 for 
interaction with the spliceosome. If the mutant protein interacts with the spliceosome, it 
forms a stable interaction and splicing cannot proceed. As the expression of these 
mutant alleles is regulated by the GAL] promoter, the strain can be propagated on 
glucose, and dominant negative activity induced by galactose. These dominant negative 
alleles facilitate the study of the interaction between Prp2 and the spliceosome. 
Figure 4.1. Restriction map of PRP2 showing position of mutations in conserved 
sequences and areas deleted. 
Al 
- 
BamHl 	 Hindffl 	 XbaI 	 PvulI 	 Saul 	BamIlI 
PRP2 	I 817bp 	 778bp 	 581bp 	579bp 	375 jp 
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Figure 4.1. Mutations were made in conserved sequences changing GKT to AKT and GKN, 
and changing SAT to LAT. 
The dominant negative mutants were generated in the conserved sequences shown in 
figure 4.1; one changing serine to leucine in the SAT box (p1.p2L.AT) was made by Mary 
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Plumpton, and two mutations in the ATP-binding site, glycine to alanine (Prp2AKT)  and 
threonine to asparagine (pp2N) were made by Elizabeth Flinn. 
When these proteins were overproduced in a wild-type background and a splicing 
extract made, they were found to inhibit splicing in vitro. Immunoprecipitation 
experiments, in which 32P-labelled pre-messenger RNA is incubated with splicing 
extracts under splicing conditions, then precipitated with anti-Prp2 antibodies, showed 
after electrophoresis of the labelled RNA that the PRP2IT  and PRP2 
GKN  mutant 
proteins form a stable association with the spliceosome (Plumpton et al, 1994; E. 
Flinn, 1994). 
In experiments designed to map the the RNA binding site of the Prp2 protein, deletions 
were made within dominant negative alleles. 
4.2 Results 
4.2.1. Deletion analysis of Prp2T,  Prp2, Prp2T proteins. 
To investigate which part of the proteins is necessary, in addition to the mutation, for 
dominant negative activity, possibly an RNA binding site, deletions were made 
downstream of the conserved region of PRP2, from XbaI to Pvull, or from Pvull to Saul 
(figure 4.1). This was carried out in pBMPRP2 carrying Prp2'", Prp2", and Prp2AJ(T 
mutations. These constructs were transformed into S1502B, a strain wild-type for 
PRP2, and tested for dominance in the presence of galactose. 
Figure 4.2 shows that when the full-length dominant negative proteins were 
overproduced in a wild type background at 30°C, the cells were unable to grow, but 
cells which expressed the shortened dominant negative alleles of Prp2'", " Prp2', and 
Prp2T all grew. That is, the deletions resulted in loss of dominance at 30°C. 
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Figure 4.2. Assay for dominant negative activity of shortened PRP2 alleles. 
PRP2'"T PRP2GKV PRP2AKT 
	




Glu 	 Gal 
Figure 4.2. Purified transformants of S 150 were suspended in sterile water and spotted onto 
selective glucose (Glu) and galactose (Gal) plates. Only the cells transformed with full-
length dominant negative alleles are inhibited from growing in the presence of galactose at 
30°C. 
The full-length p2AKT  protein was known to behave differently to the other dominant 
negative proteins, displaying dominance at or below 30°C (E. Flinn, 1994). The deleted 
forms of the dominant negative alleles were therefore tested at temperatures below 
30°C. In the case of the p2AKTM  protein, figure 4.3 shows that it retained dominance 
at 23°C and below. The PRP2AKT 2  mutation does not appear to have an effect on cell 
growth at any temperature. 
in 
Figure 4.3. Plate showing dominant negative effect of overexpressing PRP2JtK 
TAI at 
low temperatures. 
PRP2T ppp2AKflI 	PRP2AKr 2 
7 
I . 
Figure 4.3. When grown in the presence of galactose at 23°C, pBMPRP2KTM inhibits 
growth of transformants (A). At 30°C, only the full-length pBMPRP2KT is dominant (B) 
Figure 4.4 Northern analysis of S150 overexpressing PRP2AKTA1  and PRP2AKTA1. 
Figure 4.4 RNA was prepared from S 150 transformed with pBMPRP2Tl  (tracks 1 and 3) 
pBMPRP2 T (tracks 2 and 4) or pBMPRP2 T (tracks 5 and 6). Tracks 1, 2 and 5 
contain RNA from cells grown under inducing conditions (galactose). Tracks 3, 4 and 6 
contain RNA from cells grown under repressing conditions (glucose). A northern blot of 
the RNA following electrophoresis was probed with labelled rp28. 
However, northern analysis of RNA from cells grown in glycerol-lactate medium then 
induced by galactose shows cells transformed with either the pp2lTM  and Prp2%t(TA1 
mutant alleles accumulate unspliced pre-mRNA in vivo (figure 4.4). This is not seen in 
the presence of the other mutant constructs. 
79 
Figure 4.5 Western blot showing overproduction of dominant negative alleles. 
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Figure 4.5. Equal amounts of crude protein extracts as determined by Bradford assay were 
separated by SDS-PAGE and electroblotted to Immobilon-P. Track I contains protein from 
uninduced cells, tracks 2-7 contain protein from cells overproducing shortened dominant 
negative Prp2 protein (81 kDa), and track 8 contains extract overproducing full-length Prp2 
protein (lOOkDa). Other western blots have shown Prp2 °' (track 4) to be overproduced. 
Western analysis (figure 4.5) shows that where dominance is lost, as in the cases of the 
PRP2GKN and PRP2IT mutant alleles, it is not due to degradation or lack of expression 
of the mutant protein. 
4.2.2 In vitro characterisation of PRP2AKT1. 
Splicing extracts made from overexpressing PRP24tcTMin a wild-type background do not 
splice. When combined with different ratios of wild-type splicing extract, the splicing 
activity of the wild-type extract can be blocked. Figure 4.6 shows the effect of adding 
overexpressing PRP2AKT1 extract to a wild-type S 150 extract. 
Figure 4.6. Inhibition of splicing of S150 splicing extract by overexpressing 





Figure 4.6. Splicing extract made from S150 carrying pBMPRP2 1  induced by galactose 
was added to S150 splicing extract. Tracks contained the following amounts of each 
extract: 
Track 	 S150 extract (ILl) 
2 
2 	 2 
3 2 
4 	 2 





Splicing activity of S150 extract is reduced by addition of S150/ pBMPRP2TM 
extract. 
Native gel electrophoresis shows the complexes involved in splicing. In the wild type 
case, complex Ill is made first, which includes the U I and U2 snRNPs assembled on the 
pre-mRNA. This is converted to complex I , and around the time of step one of 
splicing, complex I is converted to complex II. In extracts containing high levels of 
dominant negative protein, complexes ifi and I are seen, but complex II does not form 
and no splicing takes place. 
Figure 4.7. Native gel showing splicing complexes formed by wild-type splicing 
extract and overexpressing PRP2AKT4I  extract. 




Figure 4.7. Tracks 1, 2 and 3 show formation of complexes I, II and Ill, 5, 10 and 15 
minutes after starting a splicing reaction with S150 splicing extract. Track 4 shows 
formation of complexes land III only by S 150/ pBMPRP2 1KTA1  extract after 15 minutes. 
After native gel electrophoresis of splicing complexes produced in an overexpressing 
PRP2AKTJ extract, complexes III and I are resolved. 
4.2.3 RNA binding. 
The dominant Frp2T  mutant protein is known to have little or no ATP hydrolysis 
activity. This is not due to an inability to bind RNA however, as the 
p2AKT  mutant 
protein is shown to bind poly(U) (M. McGarvey, personal communication) during the 
Prp2 protein purification procedure (Plumpton et a!, 1994). It seems therefore that 
either RNA binding fails to stimulate ATP hydrolysis, or that this protein is unable to 
bind ATP. By analogy with yeast Ras2 protein, it is a possibility that 
p1.p2AKT  is locked 
in an inactive form which is unable to bind RNA (see section 1 .11). Dominant negative 
mutants of Ras2 are known to have a higher affinity for GDP over GTP, which prevents 
the mutant protein being activated by nucleotide exchange (Powers et a!, 1989). 
As the pm2 T mutant protein retains some dominant negative activity in the z\1 form, 
poly(U) binding experiments were carried out. Splicing extracts prepared from cells 
that overproduced prp7AKTM or 
prp7Th2  in a wild-type background were incubated 
with poly(U) agarose in a procedure modified from Kim et al, 1992. 
1)100mg poly(U) agarose in a microcentrifuge tube was swollen in IM NaCl/50mM 
Tris pH 7.5 for 30 min with mixing at room temperature. The beads were then washed 
X5 with lml BP buffer/50rnM KC1 at 4°C (section 2.5.10.4). 
After the last wash was removed, I ml of the sample to be bound to poly(U) (usually 
splicing extract) was added to the beads and incubated at 4°C with gentle mixing for 2h. 
The beads were pelleted and washed X10 with lmI of 100mM KCI in BP at 4°C. 
The bound RNA was eluted with X5 0.5m1 of 150mM KCI in BP, followed by 5X 
200mM KC1 in BP and a final X5 with 250mM KCI in BP. 
30.tl aliquots of each eluted fraction were subjected to SDS-PAGE (section 2.5.2.2), 
western blotted to Immobilon P and probed with anti-Prp2 antibodies anti-55 (section 
2.5.4). 
Figure 4.8 RNA-binding by Prp2IA1. 
KC1 concentration 







Figure 4.8. Splicing extract (Ext) made from overexpressing S15O/pBMPRP2 TM cells 
was incubated with poly(U) agarose as above. 30l aliquots from each eluted fraction were 
subjected to SDS-PAGE and western blotted to Immobilon-P membrane which was probed 
with anti-55 antiserum. Most prp2T protein was eluted by 200mM KCI. 
Figure 4.8 shows that the 81kDa p rp2TM protein binds to poly(U), eluting at a slightly 
lower concentration of salt (200mM KCI) compared to the full-length pAKT protein 
(250mM KCI; Plumpton eta!, 1994 and data not shown). Similar results were obtained 
for p2AKTL2 
4.3 Discussion. 
We have shown that in the case of one dominant-negative allele of PRP2, PRP2AKT, 
some dominant negative activity is retained after deletion of certain regions from this 
protein. This was in contrast to similar deletions in other alleles that resulted in non-
functional proteins. Additionally, it has been suggested that the dominant activity may 
be linked to the RNA binding activity of Prp2 (Plumpton et al, 1994, Teigelkamp et a!, 
1994). Teigelkamp et al showed the dominant negative PRP2IT  mutant forms a stable 
association with the pre-messenger RNA in the spliceosome. Deletion or disruption of 
the RNA binding site within the Prp2 protein could cause the loss of dominant negative 
activity. The Al deletion removes a likely RNA-binding site, the QRIGR motif (Pause 
et al, 1993), and also removes half of the putative zinc finger motif. The A2 deletion 
removes the other part of the putative zinc finger sequence. Loss of dominance over 
growth is observed with all the deletions with the exception 0fpAKTM 
In the case of many RNA binding proteins, there are several domains in the one protein 
which are capable of binding RNA. These domains can work in cis (Shamoo, et a!, 
1994) or in trans (Lutz-Freyermuth, 1990), binding either one or several RNAs. The 
deletion of one or more RNA binding domain can result in decreased affinity or 
specificity of RNA binding in some proteins, whereas other proteins require all their 
RNA binding domains to function. The loss or disruption of these putative RNA 
binding domains of Prp2 may account for the loss of dominance. 
There are several differences between the PRP2AKT  mutant and other dominant negative 
alleles of PRP2. The most striking difference is that PRP2AKT  mutant exhibits 
dominance only at 30°C and lower temperatures, whereas the other dominant negative 
mutants of PRP2 are dominant at all temperatures. Biochemical studies of purified 
proteins have shown that in contrast to P LAT p2AKT protein has little or no ATP 
hydrolysis activity. GKN  has similarly a negligible rate of ATP hydrolysis but in this 
case, it is likely to be due to lack of stimulation by RNA binding, as Prp2' does not 
bind poly(U). Immunoprecipitation experiments have failed to show any association of 
Prp2 T  with the spliceosome in contrast to the stable association formed between the 
spliceosome and Prp2t'4  or Prp2 T (E. Flinn, 1994, Plumpton et al, 1994). 
In the light of these differences, it is interesting that 
prpT  is the one mutant protein 
which retains some dominant phenotype after deletion of the XbaI to Pvull (Al) 
fragment. Both the Prp2 T and Prp2 GKN  proteins are thought to be dominant negative 
by means of a stable association with the spliceosome which has been demonstrated by 
immunoprecipitation experiments (E. Flinn, 1994, Plumpton et a!, 1994). This 
association has not been shown in the case of the P rp2T protein, although unlike 
Prp2GKN p2AKT  does bind poly(U). The fact that the l deletion does not fully 
inactivate the prp2T  protein suggests that all the activity of this protein is not lost but 
an important functional domain is removed. Both the p2AKTM and Prp2 
AKTA2  proteins 
retain the ability to bind RNA, so not all function of these proteins is lost. 	If the 
dominant negative activity of prp2MT  is not due to formation of a stable association 
with the spliceosome, then removal of the spliceosome binding domain would not 
abrogate dominant function in this protein. Taken together, these results suggest that 
protein confers its dominant effect in a different way to the other dominant 
negative mutants, perhaps by sequestering some other factor which interacts with the 
Prp2 protein. 
Figure 4.9. Model of proposed action of Prp21T  protein. 
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Figure 4.9. Factor E is required for complex ill-i transition. p2AKT protein has a high 
affinity to factor E and can bind, preventing the normal function of E. p1.p2AKT  in the E-
bound form is unable to enter preformed spliceosomes. Prp2'T protein interacts transiently 
at the complex 1-11transition, but this function is overridden by the action of Prp2T. 
A model was first proposed by E.Flinn (1994) and is summarised in figure 4.9, in which 
prp2T protein binds to a factor involved in complex III to I transition. This was 
suggested by the finding that partially purified pAKT protein inhibits the formation of 
complex I when added to wild-type splicing extracts, although extracts made from 
overexpressing Prp2 AKT in a wild-type background allow the formation of both 
complexes III and I. 
The model suggests that p2AKT  sequesters a factor in splicing extracts with the result 
that complex 111 to I transition does not take place. On the basis of this model, it is 
conceivable that deleted forms of pAKT  retain some affinity for putative factor E. A 
candidate for factor E is a nucleotide exchange factor (NEF) for Prp2. If Prp2T  exerts 
dominant negative activity by sequestering a putative NEF, the domain required for this 
activity could still be present and to some extent functional in pAKThI 
M. 
Chapter five. 
A Prp2-depleted in vitro system. 
5.1 Introduction. 
The advent of a simple and efficient system for purification of Prp2 protein (Plumpton 
et al, 1994) enables many in vitro studies which are informative of the effect of 
mutations on the activity of the Prp2 protein. To assay the effect on splicing, complex 
formation, spliceosome binding and pre-mRNA binding, an in vitro system derived 
from a heat-inactivated prp2-I mutant splicing extract is currently used. A point 
mutation in prp2-1 causes a temperature-sensitive defect. Splicing extracts can be made 
from a strain carrying this mutation grown at the permissive temperature. The extracts 
can then be heat-inactivated in vitro by incubating at 36°C for one hour. Spliceosomes 
can be assembled and purified from these extracts (section 2.7.8) which do not go 
through splicing, as the Prp2 protein necessary for step I is present in a heat-inactivated 
form. However, this system assumes that Prp2 protein has only one function which is 
heat-sensitive in the mutant protein, and that the heat-inactivated protein does not 
interfere with any subsequent assays such as immunoprecipitation experiments to show 
association with the spliceosome. 
Results previously presented (E. Flinn, 1994; this thesis, chapter four) suggest that, 
potentially, Prp2 protein may have another role in splicing prior to the transient 
interaction with the spliceosome seen at step 1, which could explain the dominant 
activity of the Prp2MTht  protein. This may be an interaction with another factor, 
possibly involved in formation of complex I. It is conceivable that the heat-inactivated 
prp2-1 protein retains such a function early in splicing and is only inactivated at the step 
I stage. To investigate this possibility, an attempt was made to develop an in vitro 
system entirely lacking any form of Prp2 protein. 
Immunodepletion with anti-Prp2 antibodies was previously used in an attempt to create 
a totally Prp2-free system but with this approach it as difficult to remove sufficient Prp2 
protein, even when using a combination of different anti-Prp2 antibodies, preventing 
this from becoming a viable strategy (M. Lossky. 1988). 	One of the problems 
encountered using immunodepletion was the low efficiency of precipitation by anti-Prp2 
antibodies. A relatively large volume of antibodies (40RI)  had to be bound to 20-30p1 
PAS to deplete lOp.l of splicing extract of Prp2 resulting in dilution of the extract and 
resultant loss of activity. An attempt to compensate for this dilution by increasing the 
relative volume of splicing extract in a splicing reaction failed to increase the level of 
splicing accordingly. 
Another problem with the antibody system was the long (3-4h) incubation of splicing 
extractlPAS-anti-Prp2 at 4°C. Extract incubated alone at this temperature for this length 
of time also showed a marked decrease in splicing compared to freshly-thawed extract. 
Several adjustments were made by Lossky in order to overcome these problems. It was 
found that when extracts were not irreversibly inactivated by the immunodepletion 
process, some splicing activity remained. This can be explained by the finding that 
heat-inactivated prp2-I splicing extract can be complemented by a 40-fold dilution of 
splicing extract wild-type for PRP2 (Lin et a!, 1987), suggesting that in vitro at least, 
Prp2 protein is present in excess. 
Where extracts were irreversibly inactivated, it is a possibility that other essential 
splicing factors cross-react with the anti-Prp2 antibodies and are also depleted. Given 
the similarity between Prp2, Prpl6 and Prp22 proteins (Chen and Lin, 1990), this is 
entirely possible. 
A new strategy was developed in order to take advantage of the His-tagging system. 
Depletion of Prp2 protein from splicing extracts by Ni-NTA resin should overcome 
some of the problems presented by immunodepletion. The Ni-NTA resin has a higher 
binding affinity to Prp2'' 5 relative to that of anti-Prp2 antibodies. Using this system, it 
should be possible to deplete a splicing extract of Prp2 without the dilution problems 
presented by immunodepletion. The length of incubation at 4°C can be decreased 
relative to immunodepletion, reducing the possibility of loss of activity. 
5.2 Results. 
5.2.1 Construction of SAy2 and SAy3. 
In order to minimise the amount of Ni-NTA resin necessary for depletion of Prp2, and 
therefore avoid a large dilution effect, a strain in which the expression of PRP2 could be 
regulated was constructed. This was carried out in two stages. 
The diploid strain EFyI (a/(x, ura3-521ura3-52, /zis3-A2001his3J, ade2-101oc/ADE2, 
Iys2-801/LYS2, trpl-A1/trpI-289, LEU21leu2-3, 112, PRP21PRP2::HJS3) was 
transformed with the constitutive PRP2 plasmid pSA1O (PRP2, TRPI) and 
transformants selected on minimal medium lacking tryptophan. Transformants were 
tested for the appropriate markers and sporulated. Tetrads were dissected as previously 
described and the progeny from each tetrad tested for markers. A strain was purified 
from one of the progeny which upon testing was found to have the phenotype His, 
Trp, ade and ura. This strain was called SAy2. 
A plasmid shuffle was then performed on SAy2 to obtain the strain SAy3. SAy2 was 
transformed with pBMPRP2 (galactose-inducible PRP2, URA3) and transformants 
selected for the ability to grow on galactose plates lacking uracil. Cells were then grown 
to stationary phase twice in drop-out liquid media maintaining the selection for the 
pBMPRP2 plasmid and containing galactose to induce expression of PRP2, prior to 
plating out on similar agar. Colonies were tested for the absence of pSAlO and the 
presence of pBMPRP2S .  One such strain isolated was called SAy3. 
5.2.2. In vivo characterisation of SAy3. 
Growth curves of SAy3 in glucose and galactose media were obtained. A single colony 
was picked into YPGRA medium. Mid-log cells were pelleted and resuspended in 
either YPDA or YPGRA then used to inoculate pre-warmed and pre-aerated YPDA or 
fresh YPGRA. OD was determined over a 50 hour period, and to maintain 
logarithmic growth, the cells were diluted into fresh pre-warmed and pre-aerated media 
whenever the OD60 >  approached 0.5. Complete medium was used, as selection pressure 
for the plasmid is maintained due to the sole copy of PRP2 being plasmid-borne. 20ml 
of culture were removed at every timepoint and used to make crude protein extracts. 
Figure 5.1 clearly shows that while growth continues exponentially in the presence of 
galactose, the growth rate of cells in glucose medium slows down 16 hours after 
switching from galactose. The GAL] promoter does however, allow a low level of 
expression in the presence of glucose which allows the cells to continue growing, 
although at a much reduced rate. This is confirmed by western analysis (figure 5.2) 
which shows a dramatic decrease in the level of production of Prp2 protein after around 
four hours growth in glucose although a small amount of Prp2 protein is detectable even 
after 50 hours in glucose. 
5.2.3. Prp2-depletion of splicing extracts with Ni 2+ resin. 
SAy3 was grown to OD 600 0.5 in YMGIyLac in which the GAL! promoter is neither 
induced nor repressed, then grown in the presence of 2% glucose for four hours before 
harvesting. Splicing extracts were prepared from cells grown in this way. Cultures 






Figure 5.1 Growth Curve of SAy3 in Glucose and Galactose 
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Figure 5.1. SAy3 cells were grown in glucose (YPDA) or galactose (YPGRA) medium. 
OD6w  was measured at regular intervals and plotted against time to generate the above 
growth curve. 
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Figure 5.2. Western showing decreasing levels of production of Prp2 protein with 
increasing time of incubation in glucose medium. 
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Figure 5.2. Equal amounts of crude protein extracts as determined by Bradford assay were 
analysed by Western blotting. This shows that four hours incubation in glucose is enough to 
significantly reduce the amount of Prp2 protein present. Prp2 is still detectable after 50 
hours growth in glucose. 
Splicing extracts were further depleted of Prp2 protein by Ni-NTA resin in a batch 
procedure modified from the column purification protocol of Plumpton et al, 1994. 
40jiI (packed volume) Ni-NTA resin in a microcentrifuge tube was washed 5X with 
prewash solution at 4°C (see section 2.5.10.3 for all solutions). 
500p.l 2X sample buffer (section 2.5.10.3) was added to 5001.tl SAy3 splicing extract 
and imidazole added to a final concentration of 1mM. Splicing extract and sample 
buffer were added to the washed Ni-NTA resin and incubated at 4°C for lh with gentle 
mixing. 
The Ni-NTA resin was pelleted and the splicing extract removed and dialysed for 3h 
against buffer D at 4°C. 
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5.2.4 In vitro analysis of depleted SAy3 splicing extracts. 
SAy3 extract treated as above was used in splicing reactions. Figure 5.3 shows that 
although splicing is abrogated following the depletion process, activity cannot be 
regained by the addition of purified Prp2 protein alone, or by the addition of purified 
prp2 protein and heat-inactivated DJy85 (prp2-1) splicing extract. 
Figure 5.3. In vitro splicing by SAy3 extract before and after depletion by Ni-NTA 
resin. 
Figure 5.3. Splicing of rp28 transcript by I :SAy3, 2:SAy3depleted by Ni-NTA resin, 3: as 
track 2 but with the addition of purified P rp2S protein, 4: as track 3 but with the addition 
of heat-inactivated DJy85 (prp2- 1) extract. 
However, as the splicing activity of this extract before depletion was low, having around 
1/10 activity compared to wild-type extracts, experiments to investigate the abrogation 
of splicing by the depletion process were carried out using wild-type splicing extracts. 
Adding 2X sample buffer to wild-type splicing extract was subsequently shown to 
abolish splicing activity even after dialysis of the extract into buffer D (figure 5.4). 
Figure 5.4. Splicing is inhibited by the addition of 2X sample buffer. 





Figure 5.4. Splicing activity of S150 extract (I) is abrogated by the addition of 2X sample 
buffer (2). Following dialysis of extract treated with 2X sample buffer into buffer D, 
splicing activity is not regained (3). 
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Comparison of 2X sample buffer with splicing buffer A shows a vast difference in salt 
concentration (table 5.1). 
Table 5.1 Comparison of 2X sample buffer and splicing buffer A. 
2X Sample Buffer Splicing Buffer A 
20mM Tris pH7.9 10mM HEPES pH7.9 
20% glycerol 1.5mM MgCl 2 
IM NaCl 10mM KCI 
2mM imidazole pH7.9 
It is conceivable that the high salt concentration disrupts protein/protein or protein RNA 
interactions in the splicing extract which are unable to reform in vitro when the salt has 
been removed by dialysis. 
5.2.5 Development of splicing-compatible depletion system. 
It was found that the addition of 2X sample buffer to a wild-type splicing extract 
abolished splicing (figure 5.4). If the Prp2 protein could be depleted from the splicing 
extract without the addition of buffers detrimental to splicing, it may facilitate the 
restoration of splicing activity in such extracts. 
To determine the binding efficiency of NI-NTA resin to Prp2 protein in splicing buffer, 
Prp2 protein was purified from a splicing extract in which Prp2 has been overproduced 
in a wild-type background. Small-scale purification was carried out in a batch 
procedure with modified buffers as follows. 
400j.il Ni-NTA resin was equilibrated with splicing buffer A (section 2.5.6.1) by 
washing X5 with lml. 
0.5-ImI splicing extract was added to the prepared Ni-NTA resin and incubated at 
4°C for lh. 
3) The beads were pelleted and the splicing extract removed. 
The beads were washed X5 with ImI SCE buffer (see below) containing 50mM 
imidazole, followed by 3X imI washes with 150mM imidazole in SCE. 
Protein was eluted with 5X 0.5m1 200mM imidazole in SCE. 
SCE buffer (Splicing-compatibleElution) was based on buffer D used during 
preparation of splicing extracts (section 2.5.6.1) and is composed of 20mM HEPES 
pH7.5, 100mM KCI and 20% glycerol. 
Western analysis of wash and elution fractions (figure 5.5) shows that Prp2 protein 
binds to the Ni-NTA resin efficiently under these conditions and is eluted at the same 
irnidazole concentration (250mM) as during conventional purification (Plumpton et a!, 
1994). 
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Figure 5.5. Western analysis of 301.11 aliquots from elution fractions shows that most Prp2 
protein is eluted by 250mM Imidazole. 
Although the above system is efficient in the purification of 
ppHIS protein, 




A strain has been created in which it is possible to reduce the level of expression of 
PRP2 to slightly below that of wild-type by repression of the GAL] promoter by growth 
in the presence of glucose. Production of Prp2 protein in this strain, SAy3, is reduced 
but not abolished, even when grown in the presence of glucose for over 50 hours. 
Splicing extracts made from this strain grown in the presence of glucose splice weakly if 
at all, even after minimal (4h) exposure to glucose. Splicing in these extracts cannot be 
augmented or complemented by the addition of purified Prp2 protein, suggesting that 
depletion of Prp2 protein in vivo may result in the depletion of one or more other factors 
essential for splicing. The in vitro depletion process may also remove factors essential 
for splicing. Other proteins are eluted from the Ni-NTA resin in fractions containing 
Prp2 protein. It is possible that one of these proteins is essential for splicing activity. It 
is not inconceivable that the level of exression of PRP2 is limiting when Say3 is grown 
in glycerol-lactate medium in the absence of inducing galactose. 
Even if a depletion system is developed which does not irreversibly inactivate a splicing 
extract, there is a possibility that splicing activity will not be completely abolished. 
Only low levels of Prp2 protein are required for splicing in vitro (Lin eta!, 1987). There 
is a possibility that although p2 HIS protein is efficiently purified by the Ni-NTA resin, 
a residual amount of Prp2 may be sequestered in some way at the time of depletion so as 
to make the poly-histidine tag inaccessible. This would result in a low level of Prp2 
protein being present after the majority of Prp2 protein has been removed. 
An approach which could combine the efficiency of the Ni-NTA system with the 
specificity of the antibody depletion would be to have an epitope-tagged Prp2 expressed 
constitutively at low level which can be removed from splicing extracts using 
monoclonal antibodies. This approach may facilitate the removal of all the Prp2 
protein without the detrimental effects of glucose repression and non-specific removal 
of other splicing factors. 
Chapter six. 
The role of PRP2 in the fidelity of splicing. 
6.1 Introduction. 
As stated earlier in this thesis, Prp2, PrpI6 and Prp22 proteins are members of the 
DEAH-box subfamily of RNA-dependent ATPases. PRPI6 was first isolated as a 
mutant, prp 16-I, which suppressed an A to C mutation of the branch nucleotide. 
The prpl6-I suppressor mutation is contained in the highly conserved central domain. 
A mutation of a single conserved amino acid residue near the ATP-binding site results 
in atyrosine to asparagine change in amino acid position 386 of the Prpl6 protein. 
In vivo characterisation of the prpl6-1 mutation revealed the presence of a growth 
defect. Cells carrying the prpl6-1 mutant allele grow slower at low temperatures (18°C 
and 23°C). This growth defect is dominant and exacerbated by overexpression of the 
mutant allele, which results in a reduction in growth rate by a factor of 2.2 at 18°C 
(Schwer and Guthrie, 1992). 
In vitro characterisation has shown that prpl6-I causes accumulation of actin pre-
rnRNA and lariat-exon 2 splicing intermediate RNAs (Couto eta!, 1987). 
Purification of the PrpI6 wild-type and mutant proteins revealed that the Prpl6-1 
protein had a reduced ATP hydrolysis activity, such that the mutant protein hydrolyses 
ATP at around 10% that of the wild-type rate. 
Purified prpl6-1 protein has been reported to form a stable association with Prpl6-
depleted spliceosomes blocked at step 2 in the presence of ATP (Schwer and Guthrie, 
1991). 
Due to the similarity between Prp2 and PrpI6 proteins, and the proposal that Prpl6 
plays a role in proofreading the branch nucleotide, it was decided to investigate a 
nei 
possible role for Prp2 protein in the fidelity of splicing by creating a mutation in PRP2 
analogous to the prpló-I mutation. 
6.2 Results 
6.2.1 Construction of prp2-9. 
A T to G change was introduced at nucleotide 978 of PRP2, in pTZPRP2 by the Kunkel 
method of site-directed mutagenesis. This caused a Tyr to Asp change in the Prp2 
protein sequence equivalent to that of prpl6-1 protein. The entire Hindffl-XbaI 
fragment of a mutant pTZPRP2 was sequenced to check for other mutations, then 
subcloned into HindIII-XbaI cut pSA3. 
Figure 6.1. Complementation of DJy 36  (prp2-1) by pBMPRP2-9. 
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Figure 6.1. DJy36 cells transformed with either pBMPRP2 or pBMPRP2-9 were suspended 
in sterile water and spotted onto glucose (Glu) or galactose (Gal) plates and incubated at 
36°C. pBMPRP2-9 is unable to complement the is defect of the prp2-1 cells on glucose but 
can complement on galactose plates. 
This galactose-inducible construct, pBMprp2-9, was transformed into the temperature-
sensitive prp2-1 strain DJy36 and tested on glucose and galactose plates for 
complementation. Figure 6.1 shows that pBMprp2-9 is able to complement the ts 
growth defect at 36°C under inducing conditions on galactose, but not under repressing 
conditions on glucose. 
6.2.2 prp2-9 supports growth as sole source of PRP2 when overexpressed. 
Complementation assays using the temperature-sensitive prp2-1 strain DJy36 do not 
always reveal how functional a mutant protein is. Some zinc finger mutants can support 
growth when they are the sole source of PRP2 in the cell yet cannot complement a prp2-
I ts defect (section 3.2.11). For this reason, pBMprp2-9 was transformed into the 
disrupted diploid strain EFyI. Transformants were selected on minimal galactose 
medium lacking uracil. 
After sporulation, random spores were tested for auxotrophic markers and some found 
to be His, indicating the presence of the disrupted genomic Prp2::HIS3, and Ura, 
indicating the presence of the pBMprp2-9 plasmid. His - , Ural spores were also found. 
Figure 6.2. Complementation assay of EFy1 progeny transformed with pBMprp2-
9. 
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Figure 6.2. Haploid EFyI progeny carrying a disrupted prp2 locus can grow on galactose 
(Gal) at 36°C but not on glucose (Glu). 
Several isolates of His, Ural progeny were plated on selective glucose and galactose 
medium and incubated at 36°C. Figure 6.2 shows that pBMprp2-9 is capable of 
supporting growth at the restrictive temperature, 36°C, on galactose but not on glucose. 
This indicates that the prp2-9 protein has reduced efficiency compared to the wild-type 
Prp2 protein which can complement even during growth on glucose. 
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6.2.3 Can prp2-9 support growth when expressed from the PRP2 promoter? 
As pBMprp2-9 is unable to complement the ts defect of prp2-I cells on glucose, a 
plasmid was constructed with the prp2-9 mutant allele under the control of the PRP2 
promoter region. This was carried out over four steps (figure 6.3). 
pFL39 (ARS, CEN, TRPI) was first cut with Hind ifi, the ends filled-in using Klenow 
fragment, and ligated to form pFL39H. The cutting and end-filling of the Hind ifi site 
results in its destruction. 
The EcoRI-Sall fragment from pY2000, which includes the entire PRP2 gene and the 
promoter region, was ligated into EcoRI-SalI cut pFL39H. This construct is known as 
pSAIO. 
This intermediate construct, pSAIO, was cut with Hindu! and BarnHI and the 2.4kb 
fragment replaced with HindIII-BamHl fragment from pSA3 thus replacing the Hindffl-
XbaI sequence of PRP2 with the Sacl linker sequence. This construct containing the 
HindIII-XbaI linker is known as pSAI I. 
An 800bp HindIll-XbaI fragment carrying the prp2-9 mutation was ligated into 
pSAI I cut with Hindffl and XbaI . The resulting TRPI/prp2-9 construct under the 
control of the PRP2 promoter is known as pSA 14. pSA 14 was transformed into EFy I 
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Figure 6.3. Construction of a centromeric TRP1 plasmid with pip2-9 under the 
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The strains tested grew at all temperatures. An exaniple of one isolate growing at 36CC 
is shown in figure 6.4. 
Figure 6.4.prp2-9 supports growth when expressed from the PRP2 promoter. 
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Figure 6.4. Haploid progeny from EFy 1 transformed by pSA 14 which carry the disrupted 
genomic PRP2 locus grow on glucose plates at 23°C (a) and 36°C (b). 
These results indicate that although prp2-9 supports growth when expressed at a similar 
level to wild-type genomic PRP2, the reduced level of expression from the repressed 
GALl promoter on glucose is not enough to support growth, suggesting that the 
efficiency of the prp2-9 protein is reduced compared to wild-type Prp2 protein. 
6.2.4 -galactosidase assays. 
Two of the series of tester constructs used to characterise the prpl6-1 mutation were 
obtained (Couto et al, 1987). These plasmids contain the ACT] gene fused to lacZ 
(figure 6.5). 
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When the ACT] intron is correctly spliced, lacZ is expressed and can be measured using 
the in vitro assay for J3-galactosidase activity as detailed in section 2.5.11. The level of 
3-galactosidase activity is limited by the level of intron splicing and can therefore be 
used as an indicator of splicing activity. 
The constructs obtained contained the wild-type ACT] intron or with the G-A mutation 
at position I of the 5' splice site. Three additional mutations were made by site-directed 
mutagenesis. Intron mutants are summarised in Table 6. 1. 
The 1.4kb BanzHI-Sall fragment of pYAHB2wt was ligated into BamHI-Sall cut pTZI9 
to give pSA7. This was used as a template for the Kunkel method of site-directed 
mutagenesis. The resultant mutants were sequenced throughout the entire 1.4kb 
fragment before being ligated into Ba,nHI-Sall cut pYAHB2wt. The identity of 
recombinant plasmids was confirmed by -galactosidase assays as the relative activities 
for these mutants are known (Couto eta!, 1987). 
Table 6.1. Mutations in the 5' splice site and branchpoint sequences of ACT] 
intron in pYAHB2-series plasmids. 
Plasmid 5' splice site Branchpoint 
pYAHB2wt GUAUGU UACUAAC 
Al AUAUGU UACUAAC 
Cl CUAUGU UACUAAC 
A5 GUAUAU UACUAAC 
C259 GUAUGU UACUACC 
Intron mutations are shown in bold. 
The reporter plasmids were co-transformed into S 150-213 with the PRP2 or PRP16 
allele to be tested on a different plasmid. The co-transformants were selected on 
minimal medium lacking uracil and tryptophan. 
The two mutations in position one of the 5' splice site which almost completely abrogate 
splicing are not suppressed by any allele tested, giving negligible activity in any 
background. The 05 to A mutation, also in the 5' splice site, gives around 45% splicing, 
relative to the activity of the wild-type construct, regardless of background. In the case 
of the branchpoint mutation, prpl6-1 increases the level of splicing from a background 
of 8% to 23%, and the alleles of prp2 also seem to suppress this mutation, giving from 
18% to 24% activity. On glucose, the level of activity of all of these is between 5% and 
8%, with only the constitutive prp/6-I showing suppressor activity. These results are 
summarised in Table 6.2. 
Table 6.2 Results of -gaIactosidase assays 
Reporter No plasmid 
construct  
pBMPRP2 pBMprp2-9 pSBl(prpl6-l) 
pYAHB2wt 100% 100% 100% 100% 
pYAHB2AI - - - - 
pYAHB2CI - - - - 
pYAHB2A5 45% 45% 1 45% 45% 
pYAHB2C259 8% 19% 1 18% 23% 
Table 6.2. Values shown as % activity of wild type intron. - indicates no detectable - 
alactosidase activity (less than 1%). All cultures were grown in drop-out galactose 
medium, maintaining selection for the two plasmids. 
6.2.5 Copper resistance assays. 
The figures for the -gaIactosidase assays were averaged over several experiments, as 
the assay can be rather variable. To confirm these results, another reporter system was 
obtained (Burgess and Guthrie, 1993). This time, the CUPI gene, which allows growth 
on copper, was fused to ACT] instead of the lacZ gene (Figure 6.6). 











256 257 259 
branchpoint (wt) 	U A 	C U A 	A 	C 
,l_ .l 
branchpoint A A C 
mutations G C 
Figure 6.6. These reporter constructs were used in CUPIA strains 46 and 51, so that the 
level of splicing could be measured indirectly by growth on plates containing different 
concentrations of copper. Alleles of PRP2 or Prp16 to be tested were co-transformed into 
the CUP IA strains with the reporter constructs. Using TRPI as a selectable marker for the 
reporter constructs and URA3 as a marker for the alleles to be tested, co-transformants were 
readily selected on plates lacking tryptophan and uracil. 
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The ability of cup /L\ cells to grow in the presence of increasing concentrations of copper 
is proportional to the level of expression of the ACT] -CUP] fusion, which is limited by 
the efficiency of splicing of the ACT] intron. The following results were obtained by 
suspending colonies in sterile distilled water and spotting the cell suspension onto plates 
containing different concentrations of copper. with glucose as the carbon source. 
Mutations in all the conserved sequences in the intron were tested with these PRP2 
alleles, and also wild-type and mutant prpl6. Again no suppression was seen of the 5 
splice site mutations. However, there was some suppression in the case of some 
hranchpoint mutations. 









pBMPRP2 pBMprp2-9 pBMI25 
 (vector) 
pGl4 wild-type 1.0 1.0 1.0 1.0 1.0 
pSB47 C256A 0.18 0.18 0.10 0.10 0.10 
pSB48 I C256G 0.10 0.10 0.10 0.10 0.10 
pSB49 U257A 0.05 0.05 0.05 0.05 0.05 
pSB50 U257C 0.10 0.10 0.10 0.10 0.10 
pGlOO A259C 0.25 0.25 038 0.18 0.18 
Strong suppression is shown in bold, with weaker suppression shown in italics. pG 100 
levels differ slightly from published levels (Lesser and Guthrie, 1992) 
In most cases, the ability of each reporter gene to support growth in the presence of 
copper is similar to the published results and indicates allele-specific suppression of two 
branchpoint mutations by prp16-1. However, suppression of two branchpoint mutations 
upon overexpression of wild type PRP16 was novel. 
In 









pBMPRP2 pBMprp2-9 pBMI25 
 (vector) 
pGI4 wild type 1.0 1.0 1.0 1.0 1.0 
pSB47 C256A 0.18 0.25 0.25 0.25 0.10 
pSB48 C256G 0.10 10.10 0.10 0.10 0.10 
pSB49 U257A 0.05 0.05 0.05 0.05 0.05 
FB50 U257C 0.10 0.10 0.10 0.10 0.10 lOO A259C 0.25 0.25 0.25 0.25 0.18 
Strong suppression is shown in bold, with weaker suppression shown in italics. 
On the galactose plates, there was more growth on higher levels of copper, particularly 
in the case of the overexpressing PRP2 transformants which grew in the presence of 
0.25mM copper. However, the vector control was also growing at a higher level of 
copper. 
Several temperature-sensitive splicing mutants are known to self-suppress when grown 
on non-glucose carbon sources. An allele of REGI (Tung et a!, 1992), a negative 
regulator in glucose repression, has been shown to suppress several splicing mutants 
including rnal-1, prp2-1 and prp6-1. In the case of rnal-1, suppression is caused by 
the mutant regi allowing overproduction of rnal-1 protein. Also, rnal-1 and other 
splicing mutants are known to self-suppress at high gene copy number. 
It is exciting to hypothesise that the observed suppression of certain branchpoint 
mutations during growth on galactose may be a consequence of elevated Prp 16 protein, 
which may be able to suppress the branchpoint mutation in the ACT] intron. However, 
these data indicate that high level expression of Prp2 protein may enhance the 
suppression. 
To clarify the situation with respect to possible suppression by Prp2 protein, two alleles 
of PRP2 were tested using high copy-number plasmids with the gene under the control 
of the PRP2 promoter. These plasmids constitutively overexpress the PRP2 alleles on 
glucose. 













> 	Cl 	 Cl 	, 
 
0.18mM 




The results showed that cells constitutively expressing PRP2 grew only on the same 
copper concentration as the vector control, with only prp16-1 growing on high copper. 
6.3 Discussion. 
It has been shown that although the prp2-9 mutation does not eliminate Prp2 function, it 
decreases the efficiency of the Prp2 protein in the sense that for complementation of the 
II 
prp2-1 ts growth defect to take place, the protein must be produced at higher levels than 
the wild-type Prp2. Unlike prpl6-1, overexpression of prp2-9 does not cause a growth 
defect at low temperature. 
In the study of suppression of introri mutations, an interesting carbon-source effect came 
to light. It was also observed that overexpressing the wild-type PRP16 gene leads to 
suppression with the same allele specificity and similar efficiency to that of the prp 16-i 
mutation. In addition, growth of cells on galactose results in a similar suppressor effect, 
possibly due to increased levels of Prpl6 protein. However prpl6-1 is able to suppress 
the branchpoint mutations even at low copy. 
Many studies have been carried out to investigate splicing complex formation on 
transcripts with mutant intron sequences. Early in vitro studies failed to show binding 
of snRNPs to mutant ACT] transcripts. Vijayraghaven (Vijayraghaven et a!, 1986) used 
immobilised labelled transcripts on a column to isolate splicing complexes. Splicing 
extracts were loaded onto the column and splicing complexes formed on the labelled 
pre-mRNA were eluted after washing. Native gel electrophoresis was then used to 
investigate resulting protein/RNA complexes. These experiments failed to show 
binding of the U  snRNP or any other snRNP to RNA containing a mutant branchpoint 
sequence. This was unexpected at the time as it was thought that the UI snRNP would 
bind to the 5' splice site irrespective of the sequence of the branchpoint. 
Cheng and Abelson (1987) and Ruby and Abelson (1988) also looked at complex 
formation on ACT] transcripts containing either C256A or A259C branchpoint 
mutations. Again no complex formation was seen in vitro. 
The results of these experiments are seemingly at odds with the suppression studies of 
the mutant branchpoint by PRPI6. Assuming that Prp16 functions only at step 2, and 
that Prp16-mediated suppression also occurs at step 2, these transcripts must be 
assembled into spliceosomes and proceed through step 1. However, the network of 
interactions which allow this to occur in vivo may somehow be inhibited or disrupted in 
vitro. 
More recent studies in mammalian in vitro systems have shown that complexes do form 
on transcripts containing mutant branchpoints (Query et a!, 1996). Mammalian splicing 
requires a less highly conserved branchpoint sequence than yeast, but the branch 
adenosine residue is invariant. Nevertheless, all of the transcripts containing a 
modified branch residue formed splicing complexes. Interestingly, it was found that 
formation of complexes was strongly stimulated by the 5' splice site and only minimally 
affected by branch site mutations. 
If the same is true in the case of yeast introns i.e. the branchpoint proofreading step 
occurs after step 1, this is compatible with the observed lack of suppression by Prp2. 
Prp2 is known to act at step 1 (King and Beggs, 1990; Lin) and Query's results suggest 
that mutant introns are assembled into spliceosomes and step I is carried out. This 
leaves a lariat-exon 2 intermediate with an abnormal branch which may be suppressed 
by prpl6 mutants. 
It was found that the same suppressor effect displayed by the prp16 mutants (Burgess 
and Guthrie, 1993) can be seen simply by overexpressing wild-type PRP16. 
Prpl6 protein is known to bind to the spliceosome after lariat intron-exon 2 formation 
(Schwer and Guthrie, 1991). It can be specifically crosslinked to the 3' splice site of the 
intron (Umen and Guthrie, 1995) and has been shown to induce a conformational 
change in the spliceosome (Schwer and Guthrie, 1992). 
This would suggest that perhaps Prpl6 is not directly involved in proofreading the 
branchpoint, but may interact with a factor which does. All 6 mutant suppressor alleles 
of prpl6 isolated by Burgess and Guthrie were found to have reduced ATP hydrolysis 
activity. This has been proposed to be the basis of suppressor activity (Burgess and 
Guthrie 1993), however, this would not account for the suppression seen by 
overexpression of wild-type PRPI6. The following model proposes a mechanism 
whereby Prpl6 might mediate or modify the binding of a proofreading factor, X. When 
X is unbound or bound in an inactive conformation, splicing occurs. When X binds to 
an aberrant branchpoint, a discard pathway is activated and splicing does not occur. The 
model suggests ways by which X may be unable to activate the discard pathway in the 
presence of either mutant prpl6 or overproduced wild-type Prpl6 proteins. 
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Figure 6.8 Model suggesting mechanism of suppression by single-copy prpl6 
alleles and by overexpression of wild-type PRP16. 




1. Prpl6 interacts with the 3'splice site and with 
factor X which proofreads the branch nucleotide 
After proofreading, mutant introns are discarded 
and splicing does not take place. 
2. Interaction between mutant prpl6 and factor X 
is blocked, so proofreading does not take place 
and splicing occurs. 
161 
/ 	 • 
n Prp 167, 
3. Overproduction of Prpl6 mops up available factor X, so proofreading 
does not occur, allowing splicing to proceed. 
This differs from the published model. Burgess and Guthrie propose that as all the 
suppressor mutants have lowered ATPase activity relative to that of wild-type Prpl6, the 
suppressor phenotype might arise as a consequence of alterations in the rate of ATP 
hydrolysis. This is likened to the kinetic proofreading models proposed for translation 
and DNA replication (reviewed by Burgess and Guthrie, 1993). However, in these two 
cases, fidelity is lowered when the rate of NTP hydrolysis is raised. These proofreading 
systems, protein synthesis and DNA replication are both polymerisation processes, and 
splicing is not. 
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In the case of the above model, interaction with factor X is necessary for proofreading 
but not for step two of splicing to occur. The rate of ATP hydrolysis by PrpI6 protein 
may riot directly influence the proofreading step. 
Protein factors which interact with Prp I 6 could he sought by using the two-hybrid 
system (Fields and Song, 1989) to screen a library with Prp16 as bait. Any interacting 
factors found could be overexpressed in the presence of the Prpl6 branchpoint 
suppressor mutants to test for restoration of the fidelity of splicing. 
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Chapter seven. 
Summary and future work. 
Since PRP2 was first cloned and sequenced (Lee et al, 1984: Chen and Lin, 1990) much 
has been learned about the role in splicing of the Prp2 protein. In order to further 
dissect the function or functions of the Prp2 protein in the splicing process, several 
regions were targeted for mutagenesis. 
The first region of interest was the putative zinc finger motif which spans the PvuH site 
towards the 3' end of PRP2. Conservative substitutions appeared to have no detectable 
effect on the function of Prp2 as determined by complementation assays. Only more 
major changes, namely the non-conservative cys2 to tyr substitution and the 4-amino 
acid insertion had any significant effect in complementation assays when overexpressed 
in a prp2-1 background. This was in contrast to their effect in a background disrupted 
for PRP2 when, on expression form the PRP2 promoter, no growth defect was detected. 
The value of these mutations lies in the possibility that the Prp2 protein has more than 
one domain capable of interacting with RNA. Future mutational analysis of putative 
RNA-binding sites may use the zinc finger mutations in a search for synthetic lethals. 
Mutations in two distinct domains which appear to have no effect on Prp2 function 
alone may prove to be detrimental when in combination. 
Chapter four discusses the effect of deleting domains from Prp2 proteins carrying 
dominant-negative mutations. In the case of one dominant negative mutation, PRP2AKT, 
removing either of the two domains downstream of the dominant mutation did not 
abrogate poly(U) binding by the protein, although the bound protein was eluted from 
poly(U)-agarose at a slightly lower salt concentration than wild-type protein. A 
continuation of this deletion analysis may result in elucidation of RNA binding sites in 
Prp2. There is also a possibility that Prp2 interacts with one or more other protein 
factors during the course of the splicing reaction. The use of truncated proteins which 
retain some activity of Prp2 can be used to investigate which domains of the protein are 
necessary for protein/protein interactions. 
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In an attempt to determine if the Prp2 protein had an activity involved 111 the transition 
of splicing complex m to complex I, a system was developed for the in vivo and in vitro 
depletion of Prp2. However, inherent problems prevented this strategy from becoming 
viable. The possibility that either the in vivo or the in vitro depletion of Prp2 results in 
the depletion of one or more additional splicing factors is a major obstacle to this 
approach. 
Finally, a series of experiments to determine a possible proofreading role for Prp2 in 
splicing were carried out. The results detailed in chapter six indicate that Prp2 has no 
role in proofreading either the 5' splice site or the branchpoint sequence. Intriguingly, it 
was discovered during the course of experiments with Prp2 that the overproduction of 
wild type Prp 16 protein had a similar effect to that previously published for the prpl 6-1 
mutant. This has led to a model proposing how Prpl6 is involved in the proofreading 
of the branchpoint sequence and how suppression by both prpl6-1 and wild type Prpl6 
protein is possible. 
IN 
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